

Appendix

Global diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study

Zhiyuan Chen^{1†}, Wen Zheng^{1†}, Qianhui Wu^{1†}, Xinghui Chen^{1†}, Cheng Peng^{1†}, Yuyang Tian¹, Ruijia Sun¹, Minghan Wang¹, Xiaoyu Zhou¹, Zeyao Zhao¹, Guangjie Zhong¹, Xuemei Yan¹, Nuolan Liu¹, Feiran Hao¹, Sihong Zhao¹, Tingyu Zhuang¹, Juan Yang^{1,2}, Andrew S. Azman^{3,4}, Hongjie Yu^{1,2,5}

Author Affiliations:

1. School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
2. Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China
3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
4. Institute of Global Health, Faculty of Medicine, University of Geneva, Switzerland
5. Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China

†These authors contributed equally to this work.

Corresponding authors: Hongjie Yu, School of Public Health, Fudan University, Shanghai 200032, China; E-mail: yhj@fudan.edu.cn

Contents

COVID-19 vaccination policy.....	3
<i>Metrics included in the dataset of COVID-19 vaccination policy</i>	3
Table S1. Authorization information of COVID-19 vaccines by technical platforms and country.....	4
Table S2. Self-payment Fee , target population, and contraindications recommended by regulatory agencies.....	11
Table S3. Recommendation on the use of an additional or booster dose of COVID-19 vaccine.....	38
Table S4. Country lists of selling/donating or receiving COVID-19 vaccines.....	54
Target population for primary vaccination.....	55
<i>Method to estimate the size of target population</i>	55
Table S5. Categories and definitions of special population groups belonging to indication and contraindication lists.....	56
Table S6. Global, regional, and national target population.....	73
COVID-19 vaccine coverage.....	79
<i>Metrics included in the dataset of administered doses</i>	79
Figure S1. Proportion administered by vaccine technical platforms.....	80
Figure S2. Proportion administered by vaccine types.....	81
Figure S3. Date at which achieved one dose per 100 people in total population by countries.....	82
Figure S4. Vaccine coverage over time stratified by income groups and role of vaccine seller/donor or recipient.....	83
Figure S5. Vaccine coverage stratified by SDI quintile and WHO region.....	84
Figure S6. Corrections between vaccine coverage and country-level vaccine acceptance.....	85
Demand of COVID-19 vaccine doses.....	86
<i>Method to calculate the demand of COVID-19 vaccine doses</i>	86
Table S7. Global, regional, and national demand of vaccine dose.....	87
References.....	98

COVID-19 vaccination policy

Metrics included in the dataset of COVID-19 vaccination policy

- (1) **Authorization status.** Status includes licensure in use, emergency use authorization, conditional marketing, special access route, and recipients of COVAX or other countries.
- (2) **Indications and contraindications.** People who could and should not get vaccinated against COVID-19, recommended by governments/health departments.
- (3) **Additional/booster dose policy.** If the government/health department gives a clear definition of an additional/booster dose, we adopted it. Otherwise, we used the definition by the United States Centers for Disease Control and Prevention¹.
 - 3.1 **Target population.** Individuals who are eligible for a COVID-19 vaccine additional/booster shot.
 - 3.2 **Interval.** The time between the completion of primary immunization and additional/booster shots.
- (5) **Whether provide at no cost to individual vaccine recipients.**

Table S1. Authorization information of COVID-19 vaccines by technical platforms and country.

Vaccine	Authorization status	Use status	Country lists
Adenovirus vectored vaccine			
1. Convidecia	Conditional marketing	In use	China
	Emergency Use Authorization	In use	Argentina, Chile, Ecuador, Indonesia, Malaysia, Mexico, Pakistan
2. Covishield	Conditional marketing	Currently not in use	Canada
	Emergency Use Authorization	In use	Argentina, Bahrain, Bangladesh, Barbados, Bhutan, Botswana, Brazil, Cambodia, Cameroon, Comoros, Dominica, Egypt, Ghana, India, Iran, Laos, Madagascar, Maldives, Mauritius, Mexico, Morocco, Nepal, Nicaragua, Nigeria, Nigeria, Oman, Moldova, Saint Vincent and the Grenadines, Seychelles, South Africa, South Korea, Sri Lanka, Ukraine, Ukraine, Uzbekistan
	Recipients of COVAX or other countries	In use	Afghanistan, Angola, Ethiopia, Grenada, Guinea, Lesotho, Liberia, Malawi, Mali, Mauritania, Papua New Guinea, Saint Kitts and Nevis, Somalia, Suriname, Syria, Togo, Uganda, Yemen, Zambia, Trinidad and Tobago
3. Janssen COVID-19 Vaccine	Conditional marketing / Emergency Use Authorization	Currently not in use	Denmark, Finland, Norway, Sweden, India
	Conditional marketing	In use	Austria, Bulgaria, Canada, Croatia, Cyprus, Czechia, Estonia, France, Germany, Greece, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Romania, Slovakia, Slovenia, Spain
	Emergency Use Authorization	In use	Antigua and Barbuda, Bahamas, Bahrain, Bangladesh, Belgium, Belize, Bolivia, Botswana, Brazil, Cameroon, Chile, Colombia, Comoros, Cote d'Ivoire, Egypt, Ghana, Guinea, Hungary, Indonesia, Kenya, Kuwait, Laos, Lesotho, Libya, Madagascar, Malaysia, Marshall Islands, Mexico, Micronesia, Namibia, Nigeria, Oman, Philippines, Poland, Portugal, Rwanda, Saint Vincent and the Grenadines, Saudi Arabia,

			South Africa, South Korea, Sudan, Switzerland, Thailand, Togo, Tunisia, United Kingdom, United States, Vietnam, Zambia, Zimbabwe, Trinidad and Tobago
	Recipients of COVAX or other countries	In use	Afghanistan, Algeria, Benin, Central African Republic, Djibouti, Ethiopia, Gambia, Liberia, Malawi, Mali, Mauritania, Nepal, Palau, Papua New Guinea, Senegal, Sierra Leone, Somalia, South Sudan, Tajikistan, Tanzania, Yemen
4. Sputnik Light	Emergency Use Authorization	In use	Belarus, Mongolia, Venezuela
	Licensure	In use	Russia
5. Sputnik V	Emergency Use Authorization	Currently not in use	Maldives
	Emergency Use Authorization	In use	Albania, Algeria, Antigua and Barbuda, Argentina, Armenia, Azerbaijan, Bahrain, Bangladesh, Belarus, Bolivia, Bosnia and Herzegovina, Ecuador, Egypt, Gabon, Ghana, Guatemala, Guinea, Guyana, Honduras, Hungary, India, Iran, Iraq, Jordan, Kazakhstan, Kyrgyzstan, Libya, Mexico, Mongolia, Montenegro, Myanmar, Namibia, Nepal, Nicaragua, Nigeria, North Macedonia, Oman, Pakistan, Paraguay, Philippines, Moldova, Saint Vincent and the Grenadines, San Marino, Serbia, Seychelles, Slovakia, Sri Lanka, Syria, Tunisia, Turkmenistan, United Arab Emirates, Uzbekistan, Venezuela, Vietnam, Zimbabwe
	Licensure	In use	Russia
	Recipients of COVAX or other countries	In use	Angola
6. Vaxzevria	Conditional marketing	Currently not in use	Denmark, Norway, Sweden
	Conditional marketing	In use	Austria, Bulgaria, Canada, Croatia, Cyprus, Czechia, Estonia, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Romania, Slovakia, Slovenia, Spain,

			Vietnam
	Emergency Use Authorization	In use	Albania, Andorra, Antigua and Barbuda, Argentina, Armenia, Australia, Azerbaijan, Bahamas, Belgium, Belize, Benin, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Brunei, Burkina Faso, Cabo Verde, Chile, Colombia, Costa Rica, Cote d'Ivoire, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Georgia, Guatemala, Guyana, Honduras, Hungary, Indonesia, Iraq, Japan, Kenya, Kuwait, Kyrgyzstan, Lebanon, Libya, Malaysia, Mexico, Mongolia, Montenegro, Namibia, Nauru, Nicaragua, Niger, North Macedonia, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Saint Lucia, Saint Vincent and the Grenadines, Samoa, Saudi Arabia, Serbia, Thailand, Tunisia, Ukraine, United Arab Emirates, United Kingdom, Uruguay
	Recipients of COVAX or other countries	In use	Afghanistan, Algeria, Central African Republic, Democratic Republic of the Congo, Eswatini, Ethiopia, Fiji, Gambia, Guinea-Bissau, Jamaica, Jordan, Kiribati, Malawi, Mauritania, Mozambique, Papua New Guinea, Republic of the Congo, Rwanda, Sao Tome and Principe, Senegal, Sierra Leone, Solomon Islands, Somalia, South Sudan, Sudan, Tajikistan, Timor-Leste, Togo, Tonga, Tuvalu, Vanuatu, Zambia
Conjugate vaccine			
1. Soberana 02	Emergency Use Authorization	In use	Cuba, Iran, Nicaragua
DNA vaccine			
1. ZyCoV-D	Emergency Use Authorization	Currently not in use	India
Inactivated vaccine			
1. BBIBP-CorV	Conditional marketing	In use	China
	Emergency Use	In use	Antigua and Barbuda, Argentina, Armenia, Bahrain, Bangladesh, Barbados, Belarus, Belize, Bolivia,

	Authorization		Brunei, Cambodia, Cameroon, Comoros, Dominica, Dominican Republic, Egypt, Equatorial Guinea, Gabon, Gambia, Georgia, Guyana, Hungary, Indonesia, Iran, Iraq, Jordan, Kenya, Kyrgyzstan, Laos, Lesotho, Madagascar, Maldives, Mauritania, Mauritius, Mongolia, Montenegro, Morocco, Namibia, Nepal, Niger, Nigeria, North Macedonia, Oman, Pakistan, Paraguay, Peru, Philippines, Republic of the Congo, Saudi Arabia, Senegal, Serbia, Seychelles, Sri Lanka, Suriname, Thailand, United Arab Emirates, Venezuela, Vietnam, Zimbabwe, Trinidad and Tobago
	Recipients of COVAX or other countries	In use	Afghanistan, Angola, Burundi, Chad, Cote d'Ivoire, Ethiopia, Guinea-Bissau, Kazakhstan, Kiribati, Lebanon, Mozambique, Papua New Guinea, Rwanda, Sierra Leone, Solomon Islands, Somalia, Sudan, Tanzania, Vanuatu, Zambia
	Special access route	In use	Singapore
2. CoronaVac	Conditional marketing	In use	China
	Emergency Use Authorization	Currently not in use	Panama
	Emergency Use Authorization	In use	Albania, Azerbaijan, Bangladesh, Benin, Bosnia and Herzegovina, Botswana, Cambodia, Chile, Colombia, Djibouti, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Georgia, Guinea, Indonesia, Kazakhstan, Malaysia, Mexico, Nepal, North Macedonia, Oman, Pakistan, Paraguay, Philippines, Singapore, Thailand, Tunisia, Turkey, Ukraine, Uruguay, Venezuela, Zimbabwe
	Licensure	In use	Brazil
	Recipients of COVAX or other countries	In use	Algeria, Armenia, Libya, Mali, Moldova, Tajikistan, Timor-Leste, Togo
3. Covaxin	Emergency Use Authorization	In use	Botswana, Comoros, Guyana, India, Iran, Mauritius, Mexico, Nepal, Paraguay, Philippines, Zimbabwe

4. Covidful	Emergency Use Authorization	In use	China
5. COVIran Barekat	Emergency Use Authorization	In use	Iran
6. CoviVac	Licensure	In use	Russia
7. FAKHRAVAC	Emergency Use Authorization	In use	Iran
8. KCONVAC	Emergency Use Authorization	In use	China
9. QazVac	Emergency Use Authorization	In use	Kazakhstan, Kyrgyzstan
10. WBIP-CorV	Conditional marketing	In use	China
mRNA vaccine			
1. Comirnaty	Conditional marketing	In use	Austria, Bulgaria, Canada, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Romania, San Marino, Slovakia, Slovenia, South Korea, Spain, Sweden
	Emergency Use Authorization	In use	Albania, Andorra, Argentina, Armenia, Australia, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belgium, Belize, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Brunei, Cabo Verde, Chile, Colombia, Cook Islands, Costa Rica, Democratic Republic of the Congo, Dominican Republic, Ecuador, Egypt, El Salvador, Gabon, Georgia, Guatemala, Honduras, Hungary, Indonesia, Iraq, Israel, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Laos, Lebanon, Libya, Madagascar, Malaysia, Maldives, Marshall Islands, Mauritania, Mexico, Micronesia, Mongolia, Montenegro, Morocco, Namibia, New

			Zealand, Nigeria, Niue, North Macedonia, Norway, Oman, Pakistan, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Moldova, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Serbia, Singapore, South Africa, Sri Lanka, Suriname, Thailand, Tunisia, Turkey, Ukraine, United Arab Emirates, United Kingdom, United States, Uruguay, Vietnam, Trinidad and Tobago
	Licensure	In use	Saudi Arabia, Switzerland
	Recipients of COVAX or other countries	In use	Angola, Antigua and Barbuda, Benin, Chad, Cote d'Ivoire, Dominica, Grenada, Mauritius, Rwanda, Samoa, Sierra Leone, Sudan, Togo, Uzbekistan
2. Spikevax	Conditional marketing	In use	Austria, Bulgaria, Canada, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Romania, San Marino, Slovakia, Slovenia, Spain, Sweden
	Emergency Use Authorization	Currently not in use	India
	Emergency Use Authorization	In use	Argentina, Australia, Belgium, Botswana, Colombia, Democratic Republic of the Congo, Guatemala, Haiti, Honduras, Hungary, Indonesia, Israel, Japan, Kenya, Kuwait, Libya, Marshall Islands, Micronesia, Mongolia, Nigeria, Norway, Oman, Pakistan, Paraguay, Philippines, Poland, Portugal, Qatar, South Korea, Saint Vincent and the Grenadines, Saudi Arabia, Singapore, Sri Lanka, Suriname, Switzerland, Thailand, Ukraine, United Arab Emirates, United Kingdom, United States, Uzbekistan, Vietnam
	Recipients of COVAX or other countries	In use	Fiji, Palau, Republic of the Congo, Rwanda, Tajikistan, Tunisia
Protein subunit vaccine			
1. Abdala	Emergency Use	In use	Cuba, Nicaragua, Venezuela, Vietnam

	Authorization		
2. EpiVacCorona	Emergency Use Authorization	In use	Turkmenistan
	Licensure	In use	Russia
	Recipients of COVAX or other countries	In use	Belarus
3. Zifivax	Emergency Use Authorization	In use	China, Indonesia, Uzbekistan

Table S2. Self-payment Fee , target population, and contraindications recommended by regulatory agencies

Country	Payment	Target population	Contraindicated population	Data source
Africa				
Algeria	Free	18+	No data	http://www.xinhuanet.com/english/2020-12/21/c_139605514.htm http://www.news.cn/english/2021-09/05/c_1310168528.htm
Angola	Free	18+	No data	https://www.macaubusiness.com/angola-free-covid-19-vaccinations-should-begin-in-feb-with-priority-for-over-40s-health-minister/ https://minsa.gov.ao/ao/ https://ao.usembassy.gov/covid-19-information/
Benin	Free	18+	No data	https://documents1.worldbank.org/curated/en/936011623022343506/pdf/Project-Information-Document-Benin-COVID-19-second-Vaccines-Additional-Financing-to-COVID-19-Preparedness-and-Response-Project-P176562.pdf
Botswana	No data	18+	No data	https://fenyacovid.gov.bw/armready/
Burkina Faso	Free	No data	No data	https://bf.usembassy.gov/u-s-citizen-services/covid-19-information/
Burundi	No data	HCW; 60+; people with underlying conditions; people travelling abroad; any volunteers	No data	https://www.africanews.com/2021/10/19/burundi-begins-covid-19-vaccination-despite-hesitancy-among-its-people/
Cabo Verde	Free	18+	No data	https://reliefweb.int/report/cabo-verde/new-world-bank-support-equitable-access-covid-19-vaccines-cabo-verde

				https://cv.usembassy.gov/covid-19-information/
Cameroon	No data	No data	No data	
Central African Republic	No data	HCW; elderly people and / or people with chronic diseases	No data	https://peacekeeping.un.org/en/national-covid-19-vaccination-campaign-officially-launched-central-african-republic
Chad	No data	No data	No data	
Comoros	No data	18+	No data	https://vaksiny.gov.mg/#/signin?from=/
Cote d'Ivoire	Free	18+	No data	https://www.sante.gouv.ci/welcome/actualites/1192
Democratic Republic of the Congo	No data	HCW; 55+; People suffering from serious health conditions such as kidney disease, high blood pressure or diabetes mellitus	No data	https://healthpolicy-watch.news/dr-congo-finally-launches-covid-19-vaccinations-after-concerns-about-astrazeneca/
Equatorial Guinea	Free	No data	No data	https://gq.usembassy.gov/covid-19-information/
Eritrea	No data	No data	No data	
Eswatini	No data	12+	No data	https://twitter.com/eswatinigovern1/status/1445737600732459017?lang=ar-x-fm
Ethiopia	No data	35+; 18+ with health problems	People with a history of anaphylaxis to any component of the vaccine or an anaphylactic reaction following the first dose of this vaccine	https://www.moh.gov.et/ejcc/am/press-release-on-covid19 https://www.eph.gov.et/images/novel_coronavirus/EPHI_PHEOC_COVID-19_Weekly_Bulletin_45_English_03132021.pdf

Gabon	No data	No data	No data	
Gambia	Free	HCW; People with underlying medical condition; 65+	No data	https://www.facebook.com/permalink.php?story_fbid=526763178764376&id=100866698020695 https://www.unicef.org/wca/press-releases/first-tranche-covid-19-vaccines-arrives-gambia-covax-initiative
Ghana	Free	18+	No data	http://fdaghana.gov.gh/news-media.php?page=78 http://www.xinhuanet.com/english/2021-08/17/c_1310130940.htm
Guinea	No data	No data	No data	
Guinea-Bissau	No data	No data	No data	
Kenya	Free	18+	No data	https://www.gavi.org/vaccineswork/ins-and-outs-kenyas-covid-19-vaccine-rollout-plan
Lesotho	No data	16+	No data	https://www.gov.ls/his-majesty-launches-covid-19-vaccine-roll-out/
Liberia	Free	18+	No data	https://frontpageafricaonline.com/health/crusaders-for-peace-unicef-partner-to-end-covid-19-through-rapid-immunization/ https://lr.usembassy.gov/wp-content/uploads/sites/53/COVID-19-Vaccine-Fact-Sheet_FINAL_3Aug21.pdf
Madagascar	Free	18+	No data	https://mg.usembassy.gov/u-s-citizen-services/security-and-travel-information/covid-19-information/
Malawi	Free	18+	No data	https://mg.usembassy.gov/u-s-citizen-services/security-and-travel

				-information/covid-19-information/
Mali	No data	18+	No data	http://www.sante.gov.ml/index.php/actualites/communiqués/item/6341-lutte-contre-la-covid-19-au-mali-835-200-doses-de-sinovac-pour-poursuivre-la-campagne-de-vaccination
Mauritania	Free	No data	No data	https://www.aa.com.tr/en/africa/mauritania-begins-covid-19-vaccination-campaign/2189322
Mauritius	Free	12+	No data	https://health.govmu.org/Documents/Main%20Page/Corona/775_New%20Registration%20and%20Consent%20Form%20Covid-19%20Vaccination.pdf
Mozambique	No data	15+	Pregnant women	https://covid19.ins.gov.mz/vacina-covid-19/ https://covid19.ins.gov.mz/primeiro-ministro-lancou-esta-sexta-feira-o-plano-nacional-de-vacinacao/
Namibia	Free	18+	No data	https://www.facebook.com/permalink.php?story_fbid=813016316038040&id=339157366757273 https://www.namibian.com.na/208360/archive-read/Namibias-Covid-19-vaccine-delayed
Niger	No data	18+	No data	https://ne.usembassy.gov/u-s-citizen-services/covid-19-information/
Nigeria	Free	16+	People with allergic reactions to vaccine component	https://nphcda.gov.ng/faqs/
Republic of the Congo	Free	No data	No data	https://docs.google.com/forms/d/e/1FAIpQLSc79P2xWVijpzwYs7rJ_n661seDoHEu-ZIH69qp7jdDkLq9Aw/viewform
Rwanda	Free	18+	No data	https://www.premiumtimesng.com/news/more-news/430797-rwa

				nda-offers-free-covid-19-vaccinations-to-citizens.html https://rbc.gov.rw/index.php?id=100&tx_news_pi1%5Bnews%5D=621&tx_news_pi1%5Bday%5D=22&tx_news_pi1%5Bmonth%5D=8&tx_news_pi1%5Byear%5D=2021&cHash=de0254720f9498593147d16c69f4cf8d
Sao Tome and Principe	No data	No data	No data	
Senegal	Free	18+	No data	https://sn.usembassy.gov/covid-19-information/
Seychelles	Free	12+	No data	https://allafrica.com/stories/202108270089.html http://www.health.gov.sc/index.php/covid-19-vaccination-faqs/
Sierra Leone	Free	18+	No data	https://dhse.gov.sl/wp-content/uploads/2021/09/PUBLIC-NOTICE-covid-113092021-1-1.pdf
South Africa	Free	12+	People with a history of severe allergic reaction to any ingredient in the vaccine; people who is allergic to polyethene glycol (PEG) should not get the Pfizer vaccine, as it is one of the components; people who had a severe allergic reaction after the first dose should not get the second dose of that vaccine	https://www.sahpra.org.za/wp-content/uploads/2021/04/SAHPRA-Registration-with-conditions-for-the-Covid-19-vaccine-Janssen-Media-release-statement_final.pdf https://www.iol.co.za/sunday-tribune/news/children-over-12-now-eligible-to-receive-covid-vaccine-58327f81-c0a3-49de-b4b0-097c605fa3aa https://www.gov.za/coronavirus/faqs/vaccine
South Sudan	Free	18+	No data	https://www.afro.who.int/news/south-sudan-receives-first-batch-covid-19-vaccines-through-covax-facility https://www.afro.who.int/news/south-sudan-receives-its-first-cons

				ignment-johnson-johnson-covid-19-vaccines-through-covax
Tanzania	Free	18+	No data	https://www.afro.who.int/news/united-republic-tanzania-receives-first-covax-shipment https://tz.usembassy.gov/covid-19-information/
Togo	Free	20+	No data	https://vaccin.covid19.gouv.tg/faq/ https://vaccin.covid19.gouv.tg/strategie-vaccinale/
Uganda	No data	12+	No data	http://www.xinhuanet.com/english/africa/2021-07/26/c_1310086931.htm
Zambia	Free	18+	No data	https://www.usaid.gov/zambia/press-releases/sep-3-2021-united-states-provides-additional-67-million-covid-assistance https://www.afro.who.int/news/zambia-launches-covid-19-vaccination
Zimbabwe	Free	14+	No data	https://www.aa.com.tr/en/africa/zimbabwe-free-vaccination-to-begin-thursday/2147237 https://apnews.com/article/lifestyle-africa-health-zimbabwe-coronavirus-pandemic-3e0b007ccccf08ae285710250daa84be
Americas				
Antigua and Barbuda	Free	12+	Pregnant / breastfeeding women; persons who have severe allergic reactions to ingredients of the vaccine	https://www.facebook.com/investingforwellness/posts/1262969224143049 https://vaccineantiguabarbuda.com/faq/
Argentina	Free	12+	People with an allergic reaction to vaccine components or first dose; an acute SARS-CoV-2	https://www.argentina.gob.ar/coronavirus/vacuna/preguntas-frecuentes#7

			infection; pre-vaccination pregnancy	https://www.argentina.gob.ar/coronavirus/vacuna/preguntas-frecuentes#22
Bahamas	Free	12+	No data	https://www.bahamas.gov.bs/wps/portal/public https://vax.gov.bs/
Barbados	Free	12+	No data	https://gisbarbados.gov.bb/blog/pfizer-vaccine-now-available-to-the-general-public/
Belize	No data	12+	No data	https://www.facebook.com/Belizehealth/posts/2767419013556496
Bolivia	Free	16+	No data	https://www.unidoscontraelcovid.gob.bo/index.php/vacunas/ https://www.unidoscontraelcovid.gob.bo/index.php/2021/10/07/ministerio-de-salud-coordinara-con-educacion-para-inmunizar-contr-el-covid-19-a-menores-de-edad-entre-16-y-17-anos/
Brazil	Free	12+	People with allergic action to the first dose or any vaccine component	https://translate.googleusercontent.com/translate_f#21
Canada	Free	12+	No data	https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19/vaccines/how-vaccinated.html
Chile	Free	6+	People with a known history of severe acute allergy (anaphylaxis)	https://www.gob.cl/yomevacuno/ https://www.gob.cl/yomevacuno/preguntasfrecuentes/
Colombia	Free	12+	No data	https://www.como.gov/covidvaccine/#elementor-toc__heading-anchor-5 https://www.rcnradio.com/colombia/mayores-de-70-anos-podran-recibir-el-refuerzo-anticovid-de-su-vacuna-inicial-de-pfizer-o

Costa Rica	Free	12+	No data	https://www.ccss.sa.cr/arc/covid19/Manual_procedimientos_vacunacion_COVID.pdf
Cuba	Free	2+	No data	https://salud.msp.gob.cu/actualizacion-de-la-vacunacion-en-el-marco-de-los-estudios-de-los-candidatos-vacunales-cubanos-y-la-intervencion-sanitaria/ https://salud.msp.gob.cu/actualizacion-de-la-vacunacion-en-el-marco-de-los-estudios-de-los-candidatos-vacunales-cubanos-y-la-intervencion-sanitaria/
Dominica	No data	12+	No data	http://news.gov.dm/news/5337-pfizer-vaccines-arrive-in-dominica
Dominican Republic	No data	12+	No data	https://covid-19pharmacovigilance.paho.org/pfizer-biontech
Ecuador	No data	12+	No data	https://ec.usembassy.gov/covid-19-information-ecu-2/ https://www.coronavirusecuador.com/2021/09/inicio-vacunacion-a-poblacion-de-12-a-15-anos-en-coordinacion-entre-los-ministerios-de-salud-y-educacion/
El Salvador	Free	6+	No data	https://www.presidencia.gob.sv/la-poblacion-meta-a-vacunar-contracovid-19-incremento-a-5-9-millones-con-la-inclusion-de-los-nuevos-grupos-etarios/
Grenada	Free	12+	People with a severe allergic reaction to any ingredient in a COVID-19 vaccine	https://covid19.gov.gd/faq-vaccination/ https://caribbean.loopnews.com/content/grenada-begins-its-pfizer-vaccine-roll-out-soon

Guatemala	No data	18+	People with a fever; people with serious illness; pregnant women	https://www.mspas.gob.gt/component/jdownloads/category/890-plan-nacional-de-vacunaci%C3%B3n-contra-la-covid-19.html?Itemid=-1
Guyana	Free	18+	No data	https://www.health.gov.gy/
Haiti	Free	No data	No data	https://ht.usembassy.gov/covid-19-information/
Honduras	Free	15+; 12-15 with disability	People with allergic reaction to the first dose or vaccine component; people with a fever	http://www.salud.gob.hn/site/index.php/component/edocman/resumen-ejecutivo-ampliacion-vii-campana-de-vacunacion-covid-19-v0709 http://www.salud.gob.hn/site/index.php/component/edocman/resumen-ejecutivo-ampliacion-vii-campana-de-vacunacion-covid-19-v0709
Jamaica	Free	15+; 12-15 with underlying conditions	No data	https://vaccination.moh.gov.jm/frequently-asked-questions/
Mexico	Free	12+	People with allergic reaction to vaccine component; people received blood transfusion or monoclonal antibodies	http://vacunacovid.gob.mx/wordpress/preguntas-frecuentes/
Nicaragua	No data	No data	No data	
Panama	Free	12+	No data	http://www.minsa.gob.pa/noticia/traslado-de-insumos-y-personal-clave-en-la-estrategia-de-vacunacion-en-el-12-1
Paraguay	Free	18+	No data	https://www.gov.uk/foreign-travel-advice/paraguay/coronavirus https://www.vacunate.gov.py/index-plan-vacunacion.html
Peru	Free	18+; 12-18 with type III	No data	https://doh.gov.ph/vaccines/know-your-vaccines

		obesity, diabetes mellitus, cancer, Down syndrome, rare and orphan diseases		
Saint Kitts and Nevis	Free	12+	People who are allergic to substances in the vaccine; pregnant and breastfeeding women	https://covid19.gov.kn/covid-19-vaccination/ https://www.sknis.gov.kn/2021/08/13/pfizer-covid-19-vaccines-will-offer-protection-to-the-federations-children-12-years-and-up-minister-of-health-byron-nisbett/
Saint Lucia	Free	12+	No data	https://suntci.com/people-in-st-lucia-can-now-register-online-for-covid-vaccine-p5886-135.htm http://socialtransformation.govt.lc/news/covid-19-vaccination-update2
Saint Vincent and the Grenadines	Free	No data	No data	https://www.gov.uk/foreign-travel-advice/st-vincent-and-the-grenadines/coronavirus
Suriname	Free	18+	People with proven severe allergies to any of the components of the vaccine; pregnant women	https://laatjevaccineren.st/vragen/#vaccineren
United States	Free	12+	People with allergic reactions to vaccine component	https://www.fda.gov/media/144413/download https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html
Uruguay	Free	12+	People with allergic reactions to the first dose or vaccine component	https://www.gub.uy/ministerio-salud-publica/comunicacion/publicaciones/preguntas-frecuentes-vacunacion-covid-19/sobre-vacuna

				s/casos-indicados
Venezuela	Free	18+	No data	https://reporting.unhcr.org/sites/default/files/Panama%20operational%20update%20April%202021.pdf
Trinidad and Tobago	Free	12+	People with allergic reactions to vaccine component	https://health.gov.tt/covid-19/covid-19-vaccine/faqs
Eastern Mediterranean				
Afghanistan	No data	18+	No data	https://www.adb.org/sites/default/files/linked-documents/55012-01-sd-03.pdf
Bahrain	Free	12+; 3-11 with respiratory diseases, heart diseases, diabetes mellitus, obesity, cancer, Down syndrome and birth defects	People should not have allergies to any of the vaccine's components; women should not be pregnant or planning on getting pregnant, or lactating women	https://healthalert.gov.bh/uploads/dhep3ew1_12l.pdf https://healthalert.gov.bh/uploads/sf3iuypu_oby.pdf https://www.cvdvaccine-bh.com/files/V6_6-2-Final-121120-EUA_Full-Prescribing-Info_HCP-Fact-Sheet-Pfizer-BioNTech-COVID-19-vaccine-14-1-2021.pdf https://www.nhra.bh/Media/Announcement/MediaHandler/Generichandler/documents/Announcements/NHRA_News_MoH%20Circular_Inactivated%20COVID19%20Vaccine%20(Snopharm)_2021215n.pdf
Djibouti	No data	18+	No data	https://www.aa.com.tr/en/africa/djibouti-receives-more-covid-19-jabs-as-vaccination-drive-underway/2307470
Egypt	Free	18+	No data	https://www.egypttoday.com/Article/1/103826/Egyptians-non-Egyptians-receive-COVID-vaccine-for-free-Health-Ministry https://www.thenationalnews.com/mena/egypt-opens-vaccine-regi

				stration-for-all-citizens-over-18-1.1186403
Iran	No data	No data	No data	
Iraq	No data	18+	No data	https://www2.hse.ie/screening-and-vaccinations/covid-19-vaccine/get-the-vaccine/deciding-on-vaccination-for-12-to-15-year-olds/
Jordan	Free	12+	People with allergic reactions to vaccine component, first dose, another vaccine; pregnant or breastfeeding women	https://corona.moh.gov.jo/ar/page/1061/CoronaVaccineQuestions
Kuwait	Free	12+	No data	http://www.xinhuanet.com/english/2021-07/19/c_1310069039.htm
Lebanon	Free	16+	People with an anaphylactic shock after receiving a previous dose of this vaccine, or a severe allergic reaction to any component of this vaccine	https://www.familyfirsthealth.org/lebanon-covid-19-vaccine-clinic https://www.moph.gov.lb/userfiles/files/Prevention/COVID-19%20Vaccine/COVID-19%20Vaccine%20FAQ%20-%20EN%20-22-3-%202021.pdf https://www.moph.gov.lb/userfiles/files/Prevention/COVID-19%20Vaccine/COVID-19%20Vaccine%20FAQ%20-%20EN%20-22-3-%202021.pdf
Libya	No data	18+	Pregnant and breastfeeding women	https://www.eservices.ly/
Morocco	Free	12+	People with allergic reactions to vaccine component or the first dose; people allergic to other vaccine; pregnant or breastfeeding women; people with an infectious disease in the acute phase	https://www.africanews.com/2021/09/01/covid-19-morocco-begin-inoculating-children-over-12-years-old/ https://liqahcorona.ma/fr/page-je-minforme-sur-le-vaccin#209 https://liqahcorona.ma/fr/questions#faq

Oman	Free	12+	No data	https://www.thearabianstories.com/2021/08/15/covid-19-free-vaccination-begins-for-oman-expats-in-al-dhahirah-governorate-1/ https://om.usembassy.gov/u-s-citizen-services/covid-19-information/
Pakistan	Free	12+	No data	https://ncoc.gov.pk/covid-vaccination-en.php
Qatar	Free	12+	People with allergic reactions to vaccine component; pregnant women	https://covid19.moph.gov.qa/EN/Covid19-Vaccine/Pages/FAQ.aspx
Saudi Arabia	Free	12+	People seriously infected with SARS-CoV-2	https://www.moh.gov.sa/en/eServices/Pages/Covid19-egistration.aspx https://articlesen.covid19awareness.sa/COVID-19-Vaccine-FAQs
Somalia	Free	18+	No data	https://reliefweb.int/report/somalia/race-against-time-boost-covid-19-vaccine-uptake-somalia
Sudan	Free	18+	People with allergic reaction to the first dose; people with a fever	https://www.facebook.com/FMOH.SUDAN/posts/2986575494948742 https://www.unicef.org/sudan/stories/covid-19-vaccination-sudan
Syria	Free	18+	No data	http://www.xinhuanet.com/english/2021-05/06/c_139926698.htm http://www.emro.who.int/syria/news/update-on-covid-19-vaccination-in-syria-22-september-2021.html
Tunisia	Free	18+	No data	https://reliefweb.int/report/tunisia/tunisia-receives-first-batch-covid-19-vaccines-through-covax-facility https://reliefweb.int/report/tunisia/tunisia-receives-first-batch-covid-19-vaccines-through-covax-facility

United Arab Emirates	Free	3+	People with allergic reactions to vaccine component; pregnant women	https://u.ae/en/information-and-services/justice-safety-and-the-law/handling-the-covid-19-outbreak/vaccines-against-covid-19-in-the-uae . https://www.wam.ae/en/details/1395302961623
Yemen	Free	No data	No data	https://www.thenationalnews.com/gulf-news/yemenis-urged-to-take-covid-19-vaccine-as-first-astrazeneca-shipment-arrives-1.1194914
Europe				
Albania	Free	18+	No data	http://shendetesia.gov.al/fushata-e-vaksinimit-shqiperia-buzeqesh/
Andorra	Free	12+	No data	https://www.salut.ad/preinscripcio-vacuna-covid19/
Armenia	Free	18+	If you have a history of severe allergic reactions to any ingredients of a COVID-19 vaccine; if you are currently sick or experiencing symptoms of COVID-19.	https://www.unicef.org/armenia/en/stories/everything-you-need-know-about-covid-19-vaccination-armenia#Question1
Austria	Free	12+	Seriously allergic to first dose	https://www.sozialministerium.at/Corona-Schutzimpfung/Corona-Schutzimpfung---Fachinformationen.html
Azerbaijan	Free	12+	People with uncontrolled epilepsy; patients receiving immunosuppressive therapy; pregnant women	http://sehiyye.gov.az/xeberler/3418-azrbaycan-respublikasnn-shiyy-nazirliyi-cbari-tibbi-sorta-zr-dvlt-agentliyi-v-tibbi-razi-blmlrini-daretm-birliyinin-mlumati.html http://health.gov.az/xeberler/3477-azrbaycan-respublikas-shiyy-nazirliyinin-mlumati.html
Belarus	Free	16+	Immunosuppressive therapy	https://cms.law/en/int/expert-guides/cms-expert-guide-to-vaccine-

				compensation-regimes/belarus http://minzdrav.gov.by/ru/dlya-spetsialistov/rekomendatsii-po-vaktsinatsii-protiv-covid-19.php
Belgium	Free	12+	No data	https://www.info-coronavirus.be/en/vaccination/#faq
Bosnia and Herzegovina	No data	No data	No data	
Bulgaria	Free	12+	People who have allergic reactions to vaccine component	https://btvnovinite.bg/bulgaria/vaksina-sreshtu-covid-19-za-decainteresat-ot-roditelite-zasega-e-plah.html?fbclid=IwAR20JTPCzPxeHkEHI7NARofgzgmHPmiuucuUrjbAGh7iWdCAnI7yl8CKxow https://coronavirus.bg/bg/vaccinations/faq
Croatia	Free	16+	People with an immediate allergic reaction to any other vaccine or injection therapy	https://www.koronavirus.hr/o-covidu/892 https://www.koronavirus.hr
Cyprus	No data	12+	No data	https://www.pio.gov.cy/coronavirus/uploads/06092021_vaccination3doseEN.pdf
Czechia	Free	12+	People with allergic reaction to vaccine component	https://covid.gov.cz/en/situations/information-about-vaccine/vaccine-indication-selected-cohorts
Denmark	Free	12+	People with a severe allergic reaction to the first shot or any ingredient of the vaccine; people with a fever	https://www.sst.dk/da/corona/Vaccination/Saadan-bliver-du-vaccineret https://www.sst.dk/-/media/Udgivelser/2021/Corona/Vaccination/Notater/Vidensbank-til-almen-praksis-og-vaccinationscentre.ashx?la=da&hash=A5DF7E41671F7370E23EE58D9124B5935FA55

				D3D
Estonia	Free	12+	People with a severe allergic reaction to the first shot or any ingredient of the vaccine; people with a fever; people suffering from severe frailty syndrome, are in a very bad general condition or nearing the end of their life	https://www.kriis.ee/en/vaccination-plan-and-risk-groups https://kkk.kriis.ee/en/faq/covid-19-vaccination/vaccination-plan-and-risk-groups
Finland	Free	12+	People with allergic reactions to the first dose or vaccine component	https://thl.fi/fi/web/infektioaudit-ja-rokotukset/rokotteet-a-o/koronavirusrokotteet-eli-covid-19-rokotteet-ohjeita-ammattilaisille https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-19-latest-updates/vaccines-and-coronaviruses/suitability-of-covid-19-vaccines-for-various-groups
France	Free	12+	People with allergic reactions to the first dose or vaccine component; people with thrombocytopenia and coagulation disorders, Capillary leak syndrome; 12-17 with developed pediatric multisystem inflammatory syndrome	https://vaccination-info-service.fr/Les-maladies-et-leurs-vaccins/COVID-19
Georgia	Free	18+	Pregnant women	https://www.provax.ge/Content/files/en_Vaccination_plan.pdf https://www.provax.ge/en/
Germany	Free	12+	People with allergies to components of the COVID-19 vaccines; people with a fever	https://www.bundesgesundheitsministerium.de/coronavirus/faq-covid-19-impfung.html#c21988 https://www.rki.de/SharedDocs/FAQ/COVID-Impfen/gesamt.html

Greece	Free	12+	People with a severe allergic reaction to the first shot or any ingredient of the vaccine	People with a severe allergic reaction to the first shot or any ingredient of the vaccine
Hungary	Free	12+	No data	https://koronavirus.gov.hu/gyik https://www.nnk.gov.hu/index.php/koronavirus-tajekoztato/936-gyakori-kerdesek-valaszok-a-vakcinarol-pfizer-biontech-vakcina http://www.xinhuanet.com/english/europe/2021-06/11/c_1310001374.htm
Iceland	Free	12+	People with a history of severe allergies	https://www.lyfjastofnun.is/frettir/bolusetning-barna-og-unglinga-12-15-ara/ https://www.lyfjastofnun.is/covid-19/comirnaty-biontech-pfizer-2/ https://www.landlaeknir.is/um-embattid/greinar/grein/item44019/vaccination-against-covid-19
Ireland	Free	12+	No data	https://www2.hse.ie/screening-and-vaccinations/covid-19-vaccine/get-the-vaccine/deciding-on-vaccination-for-12-to-15-year-olds/
Israel	Free	12+	People with serious allergic reactions; people with a fever	https://govextra.gov.il/ministry-of-health/covid19-vaccine/en-covid19-vaccination-information/
Italy	Free	12+	People with allergic reactions to the first dose	https://www.aifa.gov.it/en/domande-e-risposte-su-vaccini-covid-19
Kazakhstan	Free	12+	No data	https://egov.kz/cms/en/articles/health_care/Vakcinaciya-protiv-koronavirusnoy-infekcii- https://primeminister.kz/en/news/press/deti-ot-12-let-i-starshe-sm

				ogut-poluchit-vakcinu-pfizer-tolko-na-dobrovolnoy-osnove-i-s-so glasiya-roditeley-a-coy-2782049
Kyrgyzstan	Free	18+	People with allergic reaction to vaccine component; people with a fever; people with an acute attack of chronic disease; people with epilepsy; pregnant or breastfeeding women	http://med.kg/ru/novosti/5345-kak-zashchitit-lyudej-s-osobymi-potrebnostyami-ot-sovid-19-delat-li-vaktsinatsiyu.html http://med.kg/ru/vaktsinatsiya/5037-vaktsinatsiya-lits-s-nevrologicheskim-zabolevaniyami.html
Latvia	Free	12+	People with a severe allergic reaction in the past after receiving other vaccines or medications	https://www.spkc.gov.lv/lv/manavakcinalv https://www.spkc.gov.lv/lv/visparigi-jautajumi-par-vakcinam
Lithuania	Free	12+	People with a fever	https://koronastop.lrv.lt/lt/duk/vakcinacija-nuo-covid-19/vakcinacija-nuo-12-metu-amziaus
Luxembourg	Free	12+	No data	https://covid19.public.lu/fr/vaccination/infovaxx.html
Malta	Free	12+	People with a history of serious allergy (anaphylaxis) following a vaccine or injectable medication	https://deputyprimeminister.gov.mt/en/health-promotion/covid-19/Pages/frequently-asked-questions.aspx https://deputyprimeminister.gov.mt/en/health-promotion/covid-19/Pages/travel.aspx
Moldova	Free	18+	No data	http://vaccinare.gov.md/permitted-vaccines
Monaco	Free	12+	No data	https://covid19.mc/en/fight-against-coronavirus/vaccination/qui-peut-se-faire-vacciner-contre-la-covid19/ https://covid19.mc/lutter-contre-la-covid-19/vaccination/
Montenegro	Free	12+	No data	https://www.covidodgovor.me/me/cesta-pitanja
Netherlands	Free	12+	No data	https://www.government.nl/topics/coronavirus-covid-19/dutch-vaccination-programme

North Macedonia	Free	12+	No data	http://zdravstvo.gov.mk/sq/jane-aplikuar-1-435-392-doza-te-vakines-ndersa-jane-rivaksinuar-667-739-qytetare/
Norway	Free	12+	People with allergic reactions to the first dose; people with a fever	https://www.fhi.no/publ/brev/informasjonsbrev-09.09.2021---gjenomforing-av-vaksinasjon-med-3.-dose/
Poland	Free	12+	People with allergic reactions to the first dose or vaccine component; people with immunodeficiency; pregnant or breastfeeding women	https://www.gov.pl/web/szczepimysie/narodowy-program-szczepien-przeciw-covid-19 https://www.gov.pl/web/szczepimysie/jak-sie--zaszczepic https://www.gov.pl/web/szczepimysie/pytania-i-odpowiedzi
Portugal	Free	12+	No data	https://covid19.min-saude.pt/perguntas-frequentes/ https://covid19.min-saude.pt/pedido-de-agendamento/ https://covid19.min-saude.pt/meta-alcancada-85-da-populacao-te-m-a-vacinacao-completa/
Romania	Free	12+	No data	https://vaccinare-covid.gov.ro/vaccinuri-autorizate/ https://apnews.com/article/europe-romania-coronavirus-pandemic-health-eed443fc19c966e9b07f7b14cf88c830
Russia	Free	18+	People with allergic reaction to vaccine component; people with a fever; people with an acute attack of chronic diseases; pregnant or breastfeeding women	https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/706/original/%D0%9E%D1%82%D0%B2%D0%B5%D1%82%D1%8B_%D0%BF%D0%BE_%D0%B2%D0%B0%D0%BA%D1%86%D0%B8%D0%BD%D0%B0%D1%86%D0%B8%D0%B8_COVID_19-19.02.2021-Red.pdf
San Marino	Free	12+	People with allergic reaction; People taking anticoagulant therapy	https://vaccinocovid.iss.sm/faq https://vaccinocovid.iss.sm/vaccinazione-anticovi-fascia%2012-1

				5%20anni
Serbia	Free	12+	People with fever	https://www.france24.com/en/video/20210326-go-to-serbia-for-a-free-covid-vaccine-country-offers-jabs-to-foreigners https://vakcinacija.gov.rs/vaccine-protiv-covid-19-u-srbiji/ https://borgenproject.org/covid-19-vaccinations-in-serbia/ https://vakcinacija.gov.rs/vaccine-protiv-covid-19-u-srbiji/
Slovakia	Free	12+	No data	https://www.slovenskoproticovidu.sk/sk/vsetko-o-ockovani/vakciny/viac-o-vaccine-comirnaty-od-vyrobcov-pfizer-biontech
Slovenia	Free	12+	People with severe allergy to the ingredients of the vaccine; people with a fever; people with thrombosis syndrome with thrombocytopenia after the first vaccination with Vaxzevria	https://www.nijz.si/sites/www.nijz.si/files/uploaded/priporocila_za_cepljenje_protiv_covid_uskl_psc_apr_2021.pdf https://www.cepimose.si/cepljenje-protiv-covidu-19/pogosta-vprasanja-in-odgovori/
Spain	Free	12+	People with a history of having had severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine	https://www.vacunacovid.gob.es/preguntas-y-respuestas/deben-vacunarse-los-ninos-y-las-ninas-y-la-poblacion-adolescente https://www.vacunacovid.gob.es/preguntas-y-respuestas
Sweden	Free	12+	No data	https://www.folkhalsomyndigheten.se/smittskydd-beredskap/utbrott/aktuella-utbrott/covid-19/vaccination-mot-covid-19/fragor-och-svar-om-vaccination-mot-covid-19/ https://www.1177.se/en/other-languages/other-languages/covid-19/vaccin-engelska/#section-133829
Switzerland	Free	12+	No data	https://www.swissmedicinfo.ch/ShowText.aspx?textType=FI&lang=DE&authNr=68225

Tajikistan	Free	18+	No data	https://apa.az/en/xeber/cis-countries-news/tajikistan-declares-mandatory-covid-19-vaccination-353147 https://eurasianet.org/dashboard-vaccinating-eurasia-june
Turkey	Free	12+	People with allergic reactions to the first dose or vaccine component	https://covid19asi.saglik.gov.tr/EN-78316/frequently-asked-questions.html https://www.hurriyetdailynews.com/erdogan-urges-parents-teachers-to-get-covid-19-vaccine-167672 https://www.dailysabah.com/turkey/turkey-lowers-covid-19-vaccination-age-to-15-starts-fourth-doses/news
Turkmenistan	Free	18+	No data	https://tdh.gov.tm/en/post/25815/objectives-of-increasing-national-health-system%E2%80%99s-potential-discussed https://www.barrons.com/news/uzbekistan-certifies-russia-s-sputnik-vaccine-for-mass-use-01613559912 https://www.garda.com/crisis24/news-alerts/508931/turkmenistan-authorities-tighten-covid-19-countermeasures-in-ashgabat-as-of-aug-2-update-16 https://tdh.gov.tm/en/post/25911/turkmenistan-registers-vaccines-prevention-infectious-diseases
Ukraine	Free	12+	People with any contraindications or allergies to any vaccine; people with an acute illness and body temperature above 38.5°C	https://vaccination.covid19.gov.ua/faq https://www.kyivpost.com/ukraine-politics/ukraine-allows-children-over-12-to-be-vaccinated-with-pfizer.html
United	Free	12+	No data	https://www.gov.uk/government/publications/regulatory-approval

Kingdom				-of-pfizer-biontech-vaccine-for-covid-19/information-for-uk-recipients-on-pfizerbiontech-covid-19-vaccine
Uzbekistan	Free	No data	No data	
South-East Asia				
Bangladesh	No data	18+	No data	https://www.facebook.com/opmbs/posts/from-the-statement-the-astrozeneca-vaccine-will-be-administered-to-eligible-baha/762781414443838/
Bhutan	No data	12+	People with a severe allergic reaction to the first shot or any ingredient of the vaccine; pregnant or breastfeeding women	https://drive.google.com/file/d/1UMlrII-HvD5x1q99NH50LoMP-_qjaIA/view https://www.gov.bt/covid19/03-03-21-information-series-on-covid-19-vaccines-moh/
India	Free	18+	People with a severe allergic reaction to the first shot or any ingredient of the vaccine; pregnant or breastfeeding women; people with severe illness	https://www.mohfw.gov.in/vaccinationbooklet/#page/1 https://www.mohfw.gov.in/covid_vaccination/vaccination/faqs.html#about-the-vaccine
Indonesia	Free	12+	No data	https://www.kemkes.go.id/article/view/21070200001/phase-3-vaccination-begins-targeting-vulnerable-communities-and-children-of-12-17-years-old.html
Maldives	Free	12+	People with a fever	http://health.gov.mv/Uploads/Downloads//Informations/Informations(362).pdf https://covid19.health.gov.mv/vaccination/?c=0 https://raajje.mv/104861
Myanmar	Free	55+; people with	No data	https://www.mohs.gov.mm/page/17483

		disabilities; members of the armed groups and their families from ethnic armed groups; displaced communities and temporary communities; persons with chronic and incurable diseases		
Nepal	Free	18+	No data	https://reliefweb.int/sites/reliefweb.int/files/resources/Focused%20COVID-19_Media%20Monitoring_September%202020%2C%202021.pdf
North Korea	No data	No data	No data	
Sri Lanka	Free	12+	No data	http://www.epid.gov.lk/web/index.php?option=com_content&view=article&id=131:topics-recent&Itemid=487&lang=en http://www.epid.gov.lk/web/index.php?option=com_content&view=article&id=131:topics-recent&Itemid=487&lang=en
Thailand	Free	12+	No data	https://thainews.prd.go.th/en/news/detail/TCATG210727104313781 https://www.bangkokpost.com/thailand/general/2180323/students-aged-12-18-to-get-pfizer-jabs-later-this-month
Timor-Leste	Free	18+	No data	https://reliefweb.int/report/timor-leste/timor-leste-launches-covid-

				19-vaccination-campaign
Western Pacific				
Australia	Free	12+	No data	https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/getting-vaccinated-for-covid-19
Brunei	Free	12+	No data	http://www.moh.gov.bn/Shared%20Documents/COVID-19%20Vaccine/FAQs%20General%20Covid%2019%20Vaccine_04032021.pdf https://www.thestar.com.my/aseanplus/aseanplus-news/2021/10/20/brunei-to-vaccinate-children-aged-12-17 http://www.moh.gov.bn/Shared%20Documents/COVID-19%20Vaccine/Brunei%20Darussalam%20Vaccination%20Strategy%20V2.pdf
Cambodia	Free	6+	No data	Cambodia to Administer Booster Shots to General Public from Mid-October – Cambodia News Service http://www.xinhuanet.com/english/asiapacific/2021-04/09/c_139869140.htm
China	Free	12+	Those who are allergic to the ingredients of the vaccine or who have history of allergy to the same type of vaccine; history of serious allergy to vaccines (such as acute allergic reactions, angioedema, breathing difficulty); people with uncontrolled epilepsy and other serious neurological diseases;	http://www.nhc.gov.cn/wjw/hygq/202104/8e62004e41d648d5a084b3fb7bf098ea.shtml http://english.nmpa.gov.cn/2021-04/01/c_608350.htm

			patients with fever, or acute diseases, or during acute attacks of chronic diseases, or patients with uncontrolled severe chronic diseases; women during pregnancy	
Cook Islands	Free	12+	No data	https://covid19.gov.ck/sites/default/files/2021-09/Approval%20given%20for%2012-15%20year%20old%20to%20be%20offered%20vaccine%202.pdf
Fiji	Free	15+	People with allergic reactions to the first dose	https://www.health.gov.fj/covid-19-vaccination-campaign/ https://www.health.gov.fj/children-15-17/ https://www.health.gov.fj/covid-vaccine/vaccine-faqs/
Japan	Free	12+	People with allergic reactions to vaccine component; people with a fever.	https://www.mhlw.go.jp/stf/covid-19/vaccine.html https://www.cov19-vaccine.mhlw.go.jp/qa/receive/ https://www.mhlw.go.jp/content/000759294.pdf
Kiribati	Free	18+	No data	https://www.mhms.gov.ki/single.php?id=26
Laos	Free	17+	No data	http://www.xinhuanet.com/english/asiapacific/2021-08/10/c_1310118766.htm https://www.thestar.com.my/aseanplus/aseanplus-news/2021/09/18/laos-health-ministry-advises-covid-19-vaccine-jabs-for-pregnant-women-and-older-students
Malaysia	Free	12+	People with allergic reaction to vaccine component; people with immunodeficiency	https://www.npra.gov.my/easyarticles/images/users/1047/Frequently-Asked-Questions-FAQ-about-Comirnaty-Covid-19-Vaccine.pdf

Marshall Islands	No data	18+	No data	https://www.rnz.co.nz/international/pacific-news/436910/marshall-leads-pacific-s-covid-19-vax-charge
Micronesia	Free	12+	No data	https://hsa.gov.fm/fsm-covid-19-vaccination/ https://gov.fm/index.php/component/content/article/35-pio-articles/news-and-updates/430-covid-19-vaccines-now-available-for-all-eligible-citizens-18-in-all-fsm-states
Mongolia	Free	12+	No data	https://moh.gov.mn/news/
Nauru	No data	18+	No data	http://naurugov.nr/media/146514/nauru_bulletin_03_9jul2021_228_.pdf
New Zealand	Free	12+	People with a history of anaphylaxis to any component or previous dose of mRNA-CV	https://www.health.govt.nz/our-work/immunisation-handbook-2020/5-coronavirus-disease-covid-19 https://www.health.govt.nz/our-work/immunisation-handbook-2020/5-coronavirus-disease-covid-19
Niue	Free	12+	No data	https://covid19.govt.nz/iwi-and-communities/translations/niuean/
Palau	No data	12+	No data	https://covid19.govt.nz/iwi-and-communities/translations/niuean/the-covid-19-vaccine/vaccine-basics/
Papua New Guinea	No data	18+	No data	https://postcourier.com.pg/chinese-vaccine-to-be-gazetted/
Philippines	Free	12+	People with allergic reactions to vaccine component or the first dose	https://doh.gov.ph/vaccines https://doh.gov.ph/press-release/DOH-VACCINATION-AMONG-CHILDREN-AGED-12-17-TO-START-WITH-COMORBIDITIES-AS-PART-OF-A3-GROUP

Samoa	Free	12+	People with allergic reactions to vaccine component; people with a fever; people taking anticoagulant therapy; people with immunodeficiency; pregnant women; 85+ (optional)	https://vaccinocovid.iss.sm/faq https://www.samoaoobserver.ws/category/samoa/90307
Singapore	Free	12+	No data	https://www.gov.sg/features/covid-19-vaccination
Solomon Islands	Free	18+	No data	https://solomons.gov.sb/roll-out-of-2nd-dose-of-astrazeneca-vaccine-now-underway-in-honiara/
South Korea	No data	18+	People with allergic reactions to the first dose or vaccine component; pregnant women; people with acute symptoms such as fever (37.5°C or higher)	http://english.seoul.go.kr/covid/covid-19-vaccination-guideline/
Tonga	Free	18+	No data	https://matangitonga.to/2021/08/24/tonga-fully-vaccinates-43-eligible-people-over-18?fbclid=IwAR3KFE6s_Brg8uj0JWH-YhmejAg1fdrlv-2nh95NOLu_uL510fdPSfOCeT4
Tuvalu	No data	18+	No data	https://www.facebook.com/AusHCfnfu/posts/750425468961962
Vanuatu	No data	18+	No data	https://covid19.gov.vu/index.php/vaccination/information
Vietnam	Free	12+	No data	https://en.vietnamplus.vn/ministry-grants-conditional-approval-of-pfizer-biontech-vaccine/202977.vnp http://news.chinhphu.vn/Home/Viet-Nam-plans-to-vaccinate-adolescents-aged-1218-against-COVID19-this-month/202110/45761.vgp

Abbreviation: 18+, people aged 18 years and above; HCW, healthcare workers

Table S3. Recommendation on the use of an additional or booster dose of COVID-19 vaccine

Country	Additional dose	Notes for additional dose	Booster dose	Notes for booster dose	Data source
Africa					
Andorra	Yes	Indication: People with immunodeficiency; people on dialysis; people receiving a transplant	Yes	Indication: Vulnerable people like the elderly; residents in health centers	https://www.govern.ad/comunicats/item/13197-s-inicia-l-administracio-de-la-tercera-dosi-voluntaria-als-residents-a-centres-sociosanitaris-de-gent-gran
Mauritius	No data		Yes	Indication: people receiving Sinopharm Interval: 120 d	https://govmu.org/EN/newsgov/SitePages/2021/Vaccination-campaign-for-a-third-booster-Sinopharm-dose-to-kickstart-on-23-September-2021.aspx
South Africa	Yes	Indication: people with immunosuppression	Under discussion		https://www.sanews.gov.za/south-africa/covid-19-booster-shot-immunocompromised-south-africans
Uganda	No policy		No policy		
Americas					
Brazil	Yes	Indication: People with immunosuppression Interval: 28 d	Yes	Indication: 60+; HCW Interval: 180 d	https://www.gov.br/saude/pt-br/coronavirus/vacinas/NTDoseReforo.pdf https://www.reuters.com/world/americas/brazil-provide-covid-19-booster-shots-all-people-over-60-years-old-2021-09-28/
Canada	Yes	Indication: People with moderate to severe immunocompromision	Yes	Indication: Long-term care residents; seniors living in other congregate settings Interval: 180 d	https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/statement-september-10-2021-additional-dose-covid-19-vaccine-immunocompromised-following-1-2-dose-series.html https://www.canada.ca/en/public-health/services/immunization

					/national-advisory-committee-on-immunization-naci/statement-september-28-2021-booster-dose-long-term-care-residents-seniors-living-other-congregate-settings.html?hq_e=el&hq_m=2190695&hq_l=1&hq_v=e48b482e2d
Chile	No data		Yes	Indication: People receiving Sinovac	https://www.bloomberg.com/news/articles/2021-08-05/chile-rolls-out-covid-19-booster-campaign-that-mixes-vaccines
Colombia	Yes	Indication: People with immunosuppression	Yes	Indication: 65+; 18+ with underlying conditions; pregnant women; 18+ at high-risk exposure of SARS-CoV-2; 18+ living in nursing home	https://www.como.gov/covidvaccine/#elementor-toc__heading-anchor-5
Dominican Republic	No data		Yes	Indication: 12+	https://twitter.com/RaquelPenaVice/status/1408186389204590596
Ecuador	Yes	Indication: people with weak immune systems	No data		https://www.reuters.com/world/americas/ecuador-give-immune-weakened-people-third-covid-19-vaccine-2021-08-17/
EI Salvador	No data		Yes	Indication: 18+ Interval: 120 d	https://www.presidencia.gob.sv/el-salvador-supero-el-de-aplicaciones-de-la-tercera-dosis-de-la-vacuna-anticovid-19/
Mexico	No data		No policy		
Panama	Yes	Indication: people with immunosuppression	Yes	Indication: HCW; 55+; people in nursing home; security forces; 18-54 at high	https://www.reuters.com/world/americas/panama-give-immunocompromised-people-third-covid-19-vaccine-shot-2021-09-22/

				risk of exposure; 18-54 with underlying conditions Interval: 180 d	http://www.minsa.gob.pa/noticia/comunicado-ndeg-596
Peru	No data		Yes	Indication: HCW	https://www.youtube.com/watch?v=NiqPRcPo_1A
United States	Yes	Indication: People with immunosuppression Interval: 28 d	Yes	Indication: 65+; 18+ who live in long-term care settings; 18+ who have underlying medical conditions; 18+ who work in high-risk settings; 18+ who live in high-risk settings Interval: 180 d	https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine
Uruguay	Yes	Indication: People with immunosuppression	Yes	Indication: People receiving Sinovac; 18+ Interval: 90 d	https://www.gub.uy/ministerio-salud-publica/comunicacion/noticias/administracion-dosis-refuerzo-vacuna-contra-covid-19-immunodeprimidos https://www.gub.uy/uruguaysevacuna
Eastern Mediterranean					
Bahrain	No data		Yes	Indication: 18+ Interval: 180 d	https://healthalert.gov.bh/en/category/vaccine
Egypt	No data		Under discussion		
Jordan	No data		Yes	Indication: People receiving Sinopharm	https://petra.gov.jo/Include/InnerPage.jsp?ID=36412&lang=en&name=en_news

Kuwait	No data		Yes	Indication: 18+	https://cov19vaccine.moh.gov.kw/SPCMS/CVD_19_Vaccine_Booster_Registration.aspx
Lebanon	Yes	Indication: People with immunosuppression; people receiving Sinopharm	Yes	Indication: 75+; frontline HCW	https://www.moph.gov.lb/en/Pages/127/55387/recommendations-of-the-national-committee-for-covid-19-vaccine-on-the-administration-of-the-third-dose
Oman	No data		Under discussion		
Pakistan	Yes	Indication: 12+ international travelers	No data		https://ncoc.gov.pk/covid-vaccination-en.php
Qatar	No data		Yes	Indication: 50+; people with chronic conditions which increase their risk for severe COVID-19 infection; people with immunosuppression	https://covid19.moph.gov.qa/EN/Covid19-Vaccine/Pages/FAQ.aspx https://www.gub.uy/ministerio-salud-publica/comunicacion/noticias/se-abre-agenda-terceras-dosis-18-59-anos
Saudi Arabia	No data			Indication: 60+ Interval: 240 d	https://english.alarabiya.net/coronavirus/2021/09/27/Saudi-Arabia-will-provide-third-booster-COVID-19-vaccine-dose-for-over-60-years-old
Tunisia	No data		Yes	Indication: 50+ with underlying conditions	
United Arab Emirates	No data		Yes	Indication: 60+; people with underlying condition; 18+ who receiving long-term	https://www.wam.ae/en/details/1395302977389

				health care Interval: 180 d	
Europe					
Albania	Yes	Indication: 12+ with immunosuppression	Yes	Indication: 60+; people with underlying conditions; frontline workers	https://albaniandailynews.com/news/albania-to-start-covid-19-booster-shots-for-60-plus-citizens
Austria	Yes	Indication: Personnel in old people's, nursing and retirement homes; health care personnel; personnel in mobile care, support, nursing and 24-hour care as well as caring relatives; staff in educational institutions (childcare, school, university, etc.) Interval: 270-365 d	Yes	Indication: 16+; 12+ at risk Interval: 270-365 d; 180-270 d	https://www.thelocal.at/20210827/first-austrian-state-to-start-covid-booster-shots-from-monday/
Azerbaijan	No data		Yes	Indication: HCW; 60+	https://www.azernews.az/nation/184187.html
Belgium	Yes	Indication: People with diminished immunity, caused by a particular disease or by treatment	Yes	Indication: Residents of nursing homes; 65+; patients in assisted living apartments; people in day care centers, psychogeriatric facilities and	https://www.health.belgium.be/fr/news/conference-interministrielle-sante-publique-0 https://www.info-coronavirus.be/en/vaccination/#faq

				psychiatric care homes	
Bulgaria	Yes	Indication: people with immunosuppression Interval: 28 d	Yes	Indication: Persons in old people's homes and social institutions for residential accommodation; HCW; 65+ Interval: 180 d	https://coronavirus.bg/bg/news/251
Cyprus	No data		Yes	Indication: 60+; People with underlying condition Interval: 180 d	https://www.pio.gov.cy/coronavirus/uploads/18102021--%CE%A7%CE%BF%CF%81%CE%AE%CE%B3%CE%B7%CF%83%CE%B7%203%CE%B7%CF%82%20%CE%B4%CF%8C%CF%83%CE%B7%CF%82%20%CE%B5%CE%BC%CE%B2%CE%BF%CE%BB%CE%AF%CE%BF%CF%85%20%CF%83%CE%B5%20%CE%AC%CF%84%CE%BF%CE%BC%CE%B1%2060%20%CE%B5%CF%84%CF%8E%CE%BD%20%CE%BA%CE%B1%CE%B9%20%CE%AC%CE%BD%CF%89.pdf
Czechia	Yes	Indication: People with moderate to severe immune suppression	Yes	Indication: 12+ Interval: 180 d	http://www.news.cn/english/2021-08/31/c_1310158121.htm https://covid.gov.cz/en/situations/register-vaccination/booster-and-additional-dose
Denmark	Yes	Indication: People with severely impaired immune system Interval: 30-270 d	Yes	Indication: 65+; essential workers Interval: 180 d	https://www.sst.dk/da/Nyheder/2021/Personer-med-et-svaert-nedsat-immunforsvar-bliver-nu-tilbudt-en-3_-dosis-COVID-19-vaccine https://www.sst.dk/da/corona/Vaccination/Revaccination-af-ud

					valgte-grupper
Estonia	Yes	Indication: People with a weakened immune system	Yes	Indication: 65+; 18+ requiring for a booster dose Interval: 180 d; 240 d	https://vaktsineeri.ee/en/news/third-vaccine-doses-may-be-available-in-october/ https://vaktsineeri.ee/en/news/booster-doses-will-become-available-for-key-workers/(65+,care-home inhabitant)
Finland	Yes	Indication: People with severe immunosuppression; people receiving the first and second dose less than six weeks apart	Yes	Indication: HCW; elderly residents of nursing home and the employees caring for them Interval: 21-28 d	https://thl.fi/en/web/thlfi-en/-/thl-proposes-a-third-coronavirus-vaccine-dose-for-limited-groups
France	No data		Yes	Indication: 65+; certain particularly fragile patients; people who have been vaccinated with the Janssen vaccine; Health and medico-social professionals; medical transport professionals; those 18 and over who are immunocompromised Interval: 180 d	https://vaccination-info-service.fr/Les-maladies-et-leurs-vaccins/COVID-19
Germany	Yes	Indication: People who may	No data	Indication: 70+; old people in	https://www.bundesgesundheitsministerium.de/coronavirus/fa

		not have a sufficient or rapidly decreasing immune response after a complete vaccination, including residents of care facilities, facilities for people with disabilities, other facilities with vulnerable groups, people with immunodeficiency or immunosuppression Interval: 180 d		nursing home; HCW Interval: 180 d	q-covid-19-impfung.html#c21988 https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/PM_2021-10-07.html;jsessionid=A597C1109F012BB859E304E5DFDAF898.internet101
Greece	No data		Yes	Indication: 60+; HCW	https://www.euractiv.com/section/politics/short_news/greece-offers-booster-dose-as-thousands-of-health-workers-suspended/
Hungary	No data		Yes	Indication: 18+ Interval: 120 d	https://koronavirus.gov.hu/cikkek/magyarorszag-az-also-ahol-mar-harmadik-oltasra-lehet-idopontot-foglalni
Iceland	No data		Yes	Indication: 12+ with a history of COVID-19; individuals without history of COVID-19 antibodies who were vaccinated with the Janssen vaccine; nursing home residents and other very vulnerable welfare service	https://www.landlaeknir.is/um-embattid/greinar/grein/item47460/booster-vaccinations-for-covid-19-

				recipients (60 years and older only); highly immunosuppressed individuals with continuing immunosuppression; 60+ outside nursing homes; frontline HCW	
Ireland	Yes	Indication: People with cancer, kidney diseases, HIV, transplants, genetic diseases, High dose systemic steroids, immunocompromise; people with following treatment in the last 6 months: Cyclophosphamide, Rituximab, Alemtuzumab, Cladribine, Ocrelizumab Interval: 60 d	Yes	Indication: 65+ living in Long Term Residential Care Facilities; 80+ living in the community	https://www2.hse.ie/screening-and-vaccinations/covid-19-vaccine/get-the-vaccine/weak-immune-system/ https://www2.hse.ie/screening-and-vaccinations/covid-19-vaccine/get-the-vaccine/covid-19-vaccine-booster-dose/
Israel	No data		Yes	Indication: 12+ Interval: 150 d	https://govextra.gov.il/ministry-of-health/covid19-vaccine/en-covid19-vaccination-information/ https://govextra.gov.il/ministry-of-health/covid19-vaccine/en-covid19-vaccine-faqs/
Italy	Yes	Indication: people who	Yes	Indication: 60+; vulnerable	https://www.aifa.gov.it/en/domande-e-risposte-su-vaccini-covi

		received a solid organ transplant or who are immunocompromised Interval: 28 d		people	d-19 https://www.salute.gov.it/portale/nuovocoronavirus/dettaglioComunicatiNuovoCoronavirus.jsp?lingua=italiano&id=5835
Kazakhstan	No data		Yes	Indication: 12+ Interval: 180-270 d	https://primeminister.kz/en/news/reviews/deni-sau-ult-kazakstannyn-densaulyk-saktau-ministriginin-ulityk-zhobasy-kanday-bagyttardy-iske-asyrudy-kamtidy-1895549
Kyrgyzstan	No policy		No policy		
Latvia	Yes	Indication: People with high immunosuppression Interval: 28 d	No data	Indication: 65+; 18+ in nursing home; HCW Interval: 180 d	https://www.vm.gov.lv/lv/jaunums/ari-latvija-saks-treso-vakcinu-devu-pret-covid-19-administresanu-ka-pirmie-tas-sanems-cilveki-ar-butiski-novajinatu-imuno-sistemu https://www.vm.gov.lv/lv/jaunums/uzsak-papilddevas-3-devas-vakcinaciju-pret-covid-19-senioriem-65-veselibas-aprupes-sistemas-darbiniekiem-un-sac-klientiem
Lithuania	Yes	Indication: High-risk patients with onco-hematological diseases, receiving treatment for onco-hematological diseases, on dialysis or after organ transplantation, with autoimmune diseases when receiving immunosuppressive	Yes	Indication: HCW; people with underlying conditions; 65+ Interval: 180 d	https://sam.lrv.lt/lt/naujienos/nustatyta-tvarka-kaip-trecia-doze-bus-revakcinuojami-imunosupresiniai-pacientai https://koronastop.lrv.lt/lt/duk/vakcinacija-nuo-covid-19/revakcinacija#item-1054

		therapy			
Luxembourg	Yes	Indication: Immunocompromised patients	Yes	Indication: 75+; older adults in nursing home; people on dialysis Interval: 180 d	https://sante.public.lu/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/covid-19/covid-19-annexes/CS-MI-recommandation-3eme-dose-vaccin-COVID-19-personnes-immunodeprimees.pdf https://msan.gouvernement.lu/en/actualites.gouvernement%2B/en%2Bactualites%2Btoutes_actualites%2Bcommuniques%2B2021%2B09-septembre%2B14-vaccin-dose-additionnelle.html
Malta	Yes	Indication: Old frail people; people with immunosuppression Interval: 21 d	No data		https://deputyprimeminister.gov.mt/en/health-promotion/covid-19/Pages/vaccines.aspx https://www.independent.com.mt/articles/2021-09-13/local-news/Malta-starts-giving-Covid-19-booster-shots-to-immunosuppressed-patients-6736236685
Montenegro	Yes	Indication: Vulnerable people Interval: 60 d	No data		https://www.covidodgovor.me/me/cesta-pitanja
Netherlands	Yes	Indication: People with immunosuppression	Under discussion		https://www.rivm.nl/en/covid-19-vaccination/vaccines/immunocompromised-patients#rm-why-are-some-people-with-severely-impaired-immunity-receiving-a-third-vaccination-620821-more
North Macedonia	No data		Yes	Indication: 60+; HCW; people with immunosuppression Interval: 180d	https://koronavirus.gov.mk/vesti/223104

Norway	Yes	Indication: People with immunosuppression	Yes	Indication: 65+ Interval: 180 d	https://www.fhi.no/publ/brev/ytterligere-informasjon-om-en-trjedje-dose-til-de-med-alvorlig-nedsatt-immun/ https://www.fhi.no/en/news/2021/booster-dose-for-the-elderly-and-nursing-home-residents/
Poland	Yes	Indication: 12+ with immunosuppression Interval: At least 28 d	Yes	Indication: 50+; HCW Interval: 180 d	https://www.gov.pl/web/zdrowie/komunikat-nr-12-ministra-zdrowia-w-sprawie-szczepien-przeciw-covid-19-dawka-przypominajaca-oraz-dawka-dodatkowa-uzupelnijaca-schemat-podstawowy
Portugal	Yes	Indication: People with immunosuppression	Yes	Indication: 65+; people in nursing home Interval: 180 d	https://covid19.min-saude.pt/terceira-dose-comeca-a-ser-administrada-a-idosos-com-mais-de-65-anos-e-residentes-em-lares/
Romania	No data		Yes	Indication: 12+ Interval: 180 d	https://balkaninsight.com/2021/09/23/romania-to-offer-vaccine-booster-doses-as-covid-19-surges/
Russia	No data		Yes	Indication: 18+ Interval: 180 d	
Serbia	No data		Yes	Indication: 18+ Interval: 180 d	https://www.srbija.gov.rs/vest/en/177106/third-dose-of-covid-19-vaccine-available-as-of-tomorrow.php
Slovakia	No data		Yes	Indication: 12+ Interval: 240 d	https://worldakkam.com/covid-booster-shots-will-be-available-in-slovakia-starting-monday/310423/
Slovenia	Yes	Indication: 70+ and particularly vulnerable chronic patients	No data		https://www.cepimose.si/cepljenje-proti-covidu-19/pogosta-vprasanja-in-odgovori/

Spain	Yes	Indication: People with immunosuppression; 40+ with Down Syndrome Interval: 28 d	Yes	Indication: 70+; inmates in nursing homes Interval: 180 d	https://www.vacunacovid.gob.es/preguntas-y-respuestas/quien-es-recibiran-una-dosis-adicional-de-la-vacuna https://www.vacunacovid.gob.es/preguntas-y-respuestas
Sweden	Yes	Indication: 18+ with severe immunosuppression Interval: 56 d	Yes	Indication: People in nursing home or receiving home care; 80+ Interval: 180 d	https://www.folkhalsomyndigheten.se/smittskydd-beredskap/utbrott/aktuella-utbrott/covid-19/vaccination-mot-covid-19/fragor-och-svar-om-vaccination-mot-covid-19/ https://www.1177.se/en/other-languages/other-languages/covid-19/vaccin-engelska/#section-133829
Switzerland	Yes	Indication: people with severe immunosuppression	Under discussion		https://www.ge.ch/en/getting-vaccinated-against-covid-19/faq-vaccination-against-covid-19
Turkey	Yes		No data	Indication: HCW at high risk; 50+ Interval: 90 d	https://covid19asi.saglik.gov.tr/EN-78316/frequently-asked-questions.html?Sayfa=1
United Kingdom	Yes	Indication: People with immunosuppression Interval: 60 d	Yes	Indication: 50+; HCW; 16-49 at risk of severe illness; pregnant women Interval: 180 d	https://www.gov.uk/government/news/jcvi-issues-updated-advice-on-covid-19-booster-vaccination https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-booster-vaccine/
South-East Asia					
India	No data		Under discussion		
Indonesia	No data		Yes	Indication: HCW	https://www.kemkes.go.id/article/view/21080200001/kemenke

					s-tegaskan-vaksinasi-booster-hanya-untuk-tenaga-kesehatan.html
Nepal	No data		No policy		
New Zealand	Yes	Indication: people with severe immunosuppression Interval: 56 d	Under discussion		https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-vaccines/covid-19-vaccine-health-advice/covid-19-vaccine-severely-immunocompromised-people
Sri Lanka	No data		Yes	Indication: Frontline workers; tourism staff	https://www.reuters.com/world/asia-pacific/sri-lanka-orders-covid-19-booster-shots-frontline-workers-tourism-industry-2021-10-22/
Thailand	No data		Yes	Indication: 12+	
Bhutan	No data		Under discussion		
Western Pacific					
Australia	Yes	Indication: 12+ with immunosuppression Interval: 60-180 d	No policy		https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/booster-shot-for-severely-immunocompromised-australians
Cambodia	No data		Yes	Indication: 18+ Interval: 120 d	https://cambodianewsservice.com/cambodia-to-administer-booster-shots-to-general-public-from-mid-october/
China	No data		Yes	Indication: People at high risk of exposure; 60+; international travelers	http://kw.beijing.gov.cn/art/2021/9/26/art_6722_613586.html

Cook Islands	No policy		No policy		
Japan	Yes	Interval: 240 d	Under discussion		https://www.mhlw.go.jp/content/10601000/000833964.pdf
Laos	No policy		No policy		
Malaysia	No data		No data	Indication: 18+ Interval: 180 d	https://covid-19.moh.gov.my/semasa-kkm/2021/10/kelulusan-bersyarat-pemberian-dos-penggalak-booster-dose
Micronesia	No data		Yes	Indication: 65+; 18+ with underlying conditions; 18+ at high risk of SARS-CoV-2 exposure	https://ghs.guam.gov/jic-release-no-811-four-covid-19-related-fatalities-reported-covid-19-updates-60-hospitalized-165
Mongolia	No data		Yes		https://akipress.com/news:663617:Mongolia_vaccinates_359,447_people_with_3rd_dose_of_coronavirus_vaccine/
Palau	Yes	Indication: people with immunosuppression	No data		http://www.palauhealth.org/2019nCoV/PR-old/MHHS%20PSA%20VACCINATION%203RD%20DOSE%2009092021.pdf
Philippines	No data		Under discussion		
Singapore	Yes	Indication: People with immunosuppression; people receiving Sinovac	Yes	Indication: HCW; 18+ in institutionalised settings; 30+ Interval: 180d	https://www.moh.gov.sg/news-highlights/details/updates-to-healthcare-protocols-and-implementation-of-vaccine-booster-strategy_10Sep2021 https://www.gov.sg/article/expanding-vaccine-booster-programme-to-more-individuals

South Korea	No data		Yes	Indication: 75+	https://www.reuters.com/world/asia-pacific/skorea-vaccinate-12-17-year-olds-give-boosters-elderly-2021-09-27/
Tuvalu	No policy		No policy		
Vanuatu	No policy		No policy		

Abbreviation: d, days.

Table S4. Country lists of selling/donating or receiving COVID-19 vaccines

Country role	Country lists
Selling or donating countries	Australia; Bahrain; Bhutan; Canada; China; Colombia; Iceland; Japan; Korea; Kuwait; Mauritius; Mexico; Monaco; New Zealand; Norway; Oman; The Philippines; Qatar; Saudi Arabia; Singapore; Switzerland; Austria; Belgium; Croatia; Denmark; Estonia; Finland; France; Germany; Greece; Ireland; Italy; Luxembourg; Malta; Netherlands; Poland; Portugal; Spain; Sweden; United Kingdom; United States; Vietnam; United Arab Emirates.
Recipient countries	Afghanistan; Albania; Algeria; Andorra; Angola; Antigua and Barbuda; Argentina; Armenia; Australia; Azerbaijan; Bahamas; Bahrain; Bangladesh; Barbados; Belize; Benin; Bhutan; Bolivia; Bosnia and Herzegovina; Botswana; Brazil; Brunei Darussalam; Burkina Faso; Cabo Verde; Cambodia; Cameroon; Canada; Central African Republic; Chad; Chile; China; Colombia; Comoros; Congo, Dem. Rep.; Congo, Rep.; Costa Rica; Cote d'Ivoire; Djibouti; Dominica; Dominican Republic; Ecuador; Egypt, Arab Rep.; El Salvador; Eswatini; Ethiopia; Fiji; Gabon; Gambia, The; Georgia; Ghana; Grenada; Guatemala; Guinea; Guinea-Bissau; Guyana; Haiti; Honduras; India ⁴ ; Indonesia; Iran; Iraq; Israel; Jamaica; Jordan; Kenya; Kiribati; Korea, Dem. People's Rep.; Kosovo; Kuwait; Kyrgyz Republic; Lao PDR; Lebanon; Lesotho; Liberia; Libya; Madagascar; Malawi; Malaysia; Maldives; Mali; Mauritania; Mauritius; Mexico; Micronesia; Moldova; Monaco; Mongolia; Montenegro; Morocco; Mozambique; Myanmar; Namibia; Nauru; Nepal; New Zealand; Nicaragua; Niger; Nigeria; North Korea; North Macedonia; Oman; Pakistan; Panama; Papua New Guinea; Paraguay; Peru; Philippines; Qatar; Rwanda; Samoa; Sao Tome and Principe; Saudi Arabia; Senegal; Serbia; Sierra Leone; Singapore; Solomon Islands; Somalia; South Africa; South Sudan; South Korea; Sri Lanka; St. Kitts and Nevis; St. Lucia; St. Vincent and the Grenadines; Sudan; Suriname; Syria; Tajikistan; Timor-Leste; Togo; Tonga; Trinidad and Tobago; Tunisia; Tuvalu; Uganda; Ukraine; United Arab Emirates; United Kingdom; and Northern Ireland; Tanzania; Uruguay; Uzbekistan; Vanuatu; Venezuela; Vietnam; West Bank and Gaza; Yemen, Rep.; Zambia; Zimbabwe.

The data are derived from COVAX².

Target population for primary vaccination

Method to estimate the size of target population

Metrics

Some metrics have been collected to estimate target population: 1) **Total population estimates**. The age-specific population estimates by country in 2020 were mainly derived from the UN World Population Prospects, supplemented by the WorldPop datasets for some countries with age-specific proportion unavailable. 2) **The indication groups for primary vaccination**. The population groups who are eligible for a COVID-19 vaccine, recommended by governments/health departments. Indication groups varied by countries, which might be general population with a certain age group or some specific population groups, e.g., frontline workers. 3) **The contraindication groups**. The population who should not get vaccinated against COVID-19 recommended by governments/health departments, e.g., pregnant women, people with certain underlying conditions (i.e., bleeding disorders and immune suppression), and those previously infected with SARS-CoV-2. They should be excluded from the indication groups according to the vaccination policy in each country.

Definition of special population groups

Two underlying conditions are considered in this study: bleeding disorders and immune suppression. A bleeding disorder is defined as condition in which the blood's ability to clot is impaired or at thrombotic states³. Diseases that would cause bleeding disorder are considered as a bleeding problem. In the case of immune suppression, we include categories of cancers with direct immune suppression and cancers with possible immune suppression (from treatment therapy), as well as HIV/AIDS without receiving antiretroviral therapy (ART) based on Clark's method⁴. The categories and definitions of special population groups are presented in Supplementary Table 5, in which specific causes of bleeding disorders and immune suppression defined by GBD study group were listed.

Table S5. Categories and definitions of special population groups belonging to indication and contraindication lists

Population groups	Definition	Size data available	Data source
Pregnancy-related people			
Pregnant women	-	Yes	Wang W et al, BMJ ⁵
Breastfeeding (lactation) women	-	No	-
Plan to get pregnancy	-	No	-
People working at potentially greater risk of SARS-CoV-2 infection			
Healthcare workers	Including healthcare workers, nurses and midwives	Yes	Wang W et al, BMJ ⁵
People maintaining society safety and national security	Police and military	Yes	Wang W et al, BMJ ⁵

Other essential workers	People engaging in electricity, gas, water, food, steam, air conditioning, and accommodation supply; participating in sewerage, waste management, and remediation activities; involved in domestic transportation and storage	Yes	Wang W et al, BMJ ⁵
-------------------------	---	-----	--------------------------------

People at higher risk of severe COVID-19 disease			
Residents living in nursing homes/long-care homes/centers/facilities/institutions/settings or receiving home care	Elderly people receiving long-term care at a residential care facility and at home	Partially	https://www.who.int/data/maternal-newborn-child-adolescent-ageing/indicator-explorer-new/mca/percentage-of-older-people-receiving-long-term-care-at-a-residential-care-facility-and-at-home
Vulnerable people with high risk of experiencing irreversible and devastating harm from COVID-19 due to their health conditions, which included the elderly and people with underlying medical conditions.	Underlying conditions included cardiovascular disease, chronic kidney disease, chronic respiratory disease, chronic	Yes	Clark A et al. Lancet GH ⁴ Wang W et al, BMJ ⁵

	liver disease, diabetes, cancer with direct immunosup pression, cancer without direct immunosup pression but with possible immunosup pression caused by treatment, HIV or AIDS, tuberculosis (excluding latent		
--	--	--	--

<p>infections), chronic neurological disorders, and sickle cell disorders. And target population in this category was classified into (1) people younger than 60 years with at least one underlying condition; (2) people aged 60</p>		
---	--	--

	years or older with at least one underlying conditions; (3) people aged 80 years or older without any underlying conditions.		
People with (moderate to severe) immunosuppression	Cancers with direct immune suppression: Hodgkin lymphoma; Non-Hodgkin lymphoma; Multiple myeloma;	Yes	Estimated used data from GBD 2019 ⁶

	Acute lymphoid leukemia; Chronic lymphoid leukemia; Acute myeloid leukemia; Chronic myeloid leukemia; Other leukemia; Other malignant neoplasms; Myelodyspl astic, myeloprolif erative, and other hematopoie		
--	--	--	--

tic
neoplasms
**Cancers
with
possible
immune
suppression (from
treatment
therapy):**
Lip and oral
cavity
cancer;
Nasopharyn
x cancer;
Other
pharynx
cancer;
Esophageal
cancer;
Stomach
cancer;
Colon and

	rectum cancer; Liver cancer due to hepatitis B; Liver cancer due to hepatitis B; Liver cancer due to hepatitis B; Liver cancer due to hepatitis C; Liver cancer due to alcohol use; Liver cancer due to NASH; Liver cancer due to other		
--	---	--	--

	causes; Gallbladder and biliary tract cancer; Pancreatic cancer; Larynx cancer; Tracheal, bronchus, and lung cancer; Malignant skin melanoma; Breast cancer; Cervical cancer; Uterine cancer; Ovarian cancer;	
--	---	--

	Prostate cancer; Testicular cancer; Kidney cancer; Bladder cancer; Brain and nervous system cancer; Thyroid cancer; Mesothelioma HIV/AIDS without receiving ART**		
People with bleeding disorders	Other nutritional deficiencies	Yes	Estimated used data from GBD 2019 ⁶

	<p>; Acute hepatitis A; Acute hepatitis B; Acute hepatitis C; Acute hepatitis E; Liver cancer due to hepatitis B; Liver cancer due to hepatitis C; Liver cancer due to alcohol use; Liver cancer due to other causes; Liver cancer due</p>		
--	--	--	--

	to NASH; Cirrhosis and other chronic liver diseases due to hepatitis B; Cirrhosis and other chronic liver diseases due to hepatitis C; Cirrhosis and other chronic liver diseases due to alcohol use; Cirrhosis		
--	---	--	--

	<p>and other chronic liver diseases due to other causes; Cirrhosis and other chronic liver diseases due to NAFLD; Endocrine, metabolic, blood, and immune disorders; Dengue; Yellow fever; Multiple myeloma;</p>		
--	--	--	--

	Acute lymphoid leukemia; Chronic lymphoid leukemia; Acute myeloid leukemia; Chronic myeloid leukemia; Other leukemia; Myelodyspl astic, myeloprolif erative, and other hematopoie tic neoplasms; Venomous		
--	---	--	--

	animal contact		
People on dialysis	-	No	-
Others			
International travelers	-	No	-
People previously infected with SARS-CoV-2	COVID-19 cumulative cases	Yes	
People receiving vaccines from Janssen & Janssen, Sinovac or Sinopharm	-	Partially, and was available in Chile and Uruguay*	

* For those data that are not available, we excluded them in the calculation.

** ART coverage among people living with HIV is derived from WHO⁷ and published literature^{8,9}. We assumed that countries with such value unavailable are replaced with regional data. For example, we replaced ART coverage in Sweden with average value in Europe Region (71.0%).

Estimate peoples of population size with bleeding disorders and immune suppression

Since the prevalence of the sub-categories of each disease (bleeding disorders or immune suppression) was separately reported by GBD, one person can simultaneously suffer more than one sub-category of such disease, namely multimorbidity. Thus, we estimated the number of people who suffered at least one bleeding disorders- or immune suppression-related conditions, rather than directly adding the number of sub-categories of bleeding disorders or immune suppression.

We mainly adopted the Clark's method⁴ to estimate the size of individuals with bleeding disorders or immune suppression. Here, we briefly explain this process. First, data on the prevalence (p) of sub-categories of bleeding disorders or immune suppression were extracted by age and country from GBD 2019⁶. Then, the expected proportion of individuals with at least one bleeding problems or at least one immune suppression problems were estimated, which we refer to e here. e_{bleeding} for bleeding problems was acquired by 1 minus the probability of not having a condition in any of the 26 bleeding problems $c_{\text{bleeding}i}$: $1 - [1 - p(c_{\text{bleeding}1})] \times [1 - p(c_{\text{bleeding}2})] \times \dots \times [1 - p(c_{\text{bleeding}27})]$; and e_{immuno} for immunosuppression was acquired by 1 minus the probability of not having a condition in any of the 40 immunosuppression problems $c_{\text{immuno}i}$: $1 - [1 - p(c_{\text{immuno}1})] \times [1 - p(c_{\text{immuno}2})] \times \dots \times [1 - p(c_{\text{immuno}40})]$. Subsequently, the observed proportion (P) of people with at least one underlying condition was calculated by $P = e \times r$, where r was the ratio between the observed and expected percentage of individuals with at least one condition, with details in Clark et al⁴.

14 types of sub-diseases are considered as both bleeding disorders and immune suppression, including multiple myeloma, acute lymphoid leukemia, chronic lymphoid leukemia, acute myeloid leukemia, chronic myeloid leukemia, other leukemia, myelodysplastic, myeloproliferative, other hematopoietic neoplasms, liver cancer due to hepatitis B, liver cancer due to hepatitis C, liver cancer due to alcohol use, liver cancer due to other causes, and liver cancer due to nonalcoholic steatohepatitis (NASH). When calculating the proportion of individuals with at least one underlying conditions for these sub-diseases, we counted them once: $(1 - [1 - p(c_{\text{bleeding}1})] \times [1 - p(c_{\text{bleeding}2})] \times \dots \times [1 - p(c_{\text{bleeding}26})] \times [1 - p(c_{\text{immuno}1})] \times [1 - p(c_{\text{immuno}2})] \times \dots \times [1 - p(c_{\text{immuno}26})]) \times r$.

Estimate population size of target population

We calculated the country-specific number of contraindication groups by adding the size of pregnant women, people with certain underlying conditions, and those previously infected with SARS-CoV-2 according to the national immunization policy. Then, we estimated the size of target population for primary immunization by subtracting the population of contraindications group from the population of indication groups.

Table S6. Global, regional, and national target population.

Locations	No. of total population (million)	No. of unapproved age groups (million)	No. of contraindication population (million)	Target population (million)
Global				
Total	7750.0	2074.5	132.1	5525.6
WHO regions				
AFR	1120.2	587.7	9.4	531.1
AMR	1018.1	186.9	40.2	791.1
EMR	725.7	240.9	8.7	476.1
EUR	932.9	149.2	23.2	760.4
SEAR	2021.4	618.2	29.9	1347.5
WPR	1931.7	291.6	20.7	1619.5
Country				
Afghanistan	38.9	19.1	-	19.8
Albania	2.9	0.6	-	2.3
Algeria	43.9	15.3	-	28.6
Andorra	0.1	0.0	-	0.1
Angola	32.9	17.5	-	15.4
Antigua and Barbuda	0.1	0.0	0.0	0.1
Argentina	45.2	8.9	0.8	35.5
Armenia	3.0	0.7	0.0	2.2
Australia	25.5	4.0	0.3	21.2
Austria	9.0	1.0	0.1	7.9
Azerbaijan	10.1	2.0	0.2	8.0
Bahamas	0.4	0.1	-	0.3
Bahrain	1.7	0.3	0.0	1.4
Bangladesh	164.7	53.4	-	111.3
Barbados	0.3	0.0	-	0.2
Belarus	9.4	1.7	0.3	7.4
Belgium	11.6	1.6	0.1	9.9
Belize	0.4	0.1	-	0.3
Benin	12.1	5.9	-	6.2
Bhutan	0.8	0.2	0.0	0.6
Bolivia	11.7	3.8	0.3	7.7
Bosnia and Herzegovina	3.3	0.4	-	2.9
Botswana	2.4	0.9	-	1.4

Brazil	212.6	35.0	3.0	174.6
Brunei	0.4	0.1	0.0	0.4
Bulgaria	6.9	0.8	-	6.2
Burkina Faso	20.9	10.7	-	10.2
Burundi	11.9	11.4	-	1.7
Cabo Verde	0.6	0.2	-	0.4
Cambodia	16.7	2.1	-	14.6
Cameroon	26.5	12.9	-	13.6
Canada	37.7	4.8	0.4	32.6
Central African Republic	4.8	4.7	-	0.8
Chad	16.4	6.4	-	10.1
Chile	19.1	1.4	0.2	17.5
China	1439.3	204.8	15.7	1218.8
Colombia	50.9	8.9	0.8	41.2
Comoros	0.9	0.4	-	0.5
Congo	5.5	2.6	-	2.9
Cook Islands	0.0	0.0	0.0	0.0
Costa Rica	5.1	0.8	-	4.2
Cote d'Ivoire	26.4	12.7	-	13.6
Croatia	4.1	0.6	0.0	3.4
Cuba	11.3	0.2	-	11.1
Cyprus	1.2	0.2	-	1.0
Czechia	10.7	1.3	0.1	9.2
Democratic Republic of the Congo	89.6	83.4	-	15.5
Denmark	5.8	0.7	0.1	5.0
Djibouti	1.0	0.3	-	0.6
Dominica	0.1	0.0	-	0.1
Dominican Republic	10.8	2.4	0.2	8.2
Ecuador	17.6	3.9	-	13.7
Egypt	102.3	40.0	-	62.3
El Salvador	6.5	0.7	0.1	5.7
Equatorial Guinea	1.4	0.6	-	0.8
Eritrea	3.5	-	-	-

Estonia	1.3	0.2	0.0	1.1
Eswatini	1.2	0.3	-	0.8
Ethiopia	115.0	87.8	-	27.1
Fiji	0.9	0.3	0.0	0.6
Finland	5.5	0.7	0.0	4.8
France	65.3	9.1	13.8	42.3
Gabon	2.2	0.7	-	1.5
Gambia	2.4	2.4	-	0.3
Georgia	4.0	0.9	0.1	3.0
Germany	83.8	9.4	0.8	73.6
Ghana	31.1	13.5	-	17.6
Greece	10.4	1.1	-	9.3
Grenada	0.1	0.0	0.0	0.1
Guatemala	17.9	7.1	0.4	10.3
Guinea	13.1	6.6	-	6.5
Guinea-Bissau	2.0	1.0	-	1.0
Guyana	0.8	0.3	-	0.5
Haiti	11.4	4.4	-	7.0
Honduras	9.9	3.0	0.2	6.7
Hungary	9.7	1.1	0.1	8.5
Iceland	0.3	0.1	0.0	0.3
India	1380.0	436.9	24.6	918.5
Indonesia	273.5	57.2	4.9	211.3
Iran	84.0	24.1	-	59.8
Iraq	40.2	17.7	-	22.5
Ireland	4.9	0.8	0.1	4.1
Israel	8.7	2.0	0.2	6.5
Italy	60.5	6.1	0.4	53.9
Jamaica	3.0	0.7	0.0	2.2
Japan	126.5	12.4	0.9	113.1
Jordan	10.2	2.7	0.2	7.3
Kazakhstan	18.8	4.6	-	14.2
Kenya	53.8	24.4	-	29.3
Kiribati	0.1	0.0	-	0.1
Kuwait	4.3	0.7	-	3.5
Kyrgyzstan	6.5	2.4	0.2	3.9
Laos	7.3	2.6	0.2	4.5

Latvia	1.9	0.2	0.0	1.6
Lebanon	6.8	1.8	0.1	4.9
Lesotho	2.1	0.7	-	1.4
Liberia	5.1	2.4	-	2.7
Libya	6.9	2.3	0.1	4.5
Lithuania	2.7	0.4	-	2.4
Luxembourg	0.6	0.1	-	0.5
Macedonia	2.1	0.3	-	1.8
Madagascar	27.7	12.9	-	14.8
Malawi	19.1	9.6	-	9.6
Malaysia	32.4	6.1	0.8	25.5
Maldives	0.5	0.1	-	0.5
Mali	20.3	10.9	-	9.3
Malta	0.4	0.1	0.0	0.4
Marshall Islands	0.1	0.0	-	0.0
Mauritania	4.6	1.5	-	3.1
Mauritius	1.3	0.2	-	1.1
Mexico	128.9	26.6	29.8	72.5
Micronesia	0.1	0.0	-	0.1
Moldova	4.0	0.8	-	3.3
Monaco	0.0	0.0	-	0.0
Mongolia	3.3	0.9	-	2.4
Montenegro	0.6	0.1	0.0	0.5
Morocco	36.9	8.0	0.7	28.2
Mozambique	31.3	13.8	1.2	16.3
Myanmar	54.4	46.4	-	8.0
Namibia	2.5	1.1	-	1.5
Nauru	0.0	0.0	-	0.0
Nepal	29.1	10.3	-	18.9
Netherlands	17.1	2.1	-	15.0
New Zealand	4.8	0.7	0.1	4.0
Nicaragua	6.6	2.3	-	4.3
Niger	24.2	13.7	-	10.5
Nigeria	206.1	94.3	7.8	104.0
Niue	0.0	0.0	-	0.0
North Korea	25.8	-	-	-
Norway	5.4	0.7	-	4.7

Oman	5.1	1.0	-	4.1
Pakistan	220.9	63.1	6.2	151.6
Palau	0.0	0.0	-	0.0
Panama	4.3	0.9	-	3.4
Papua New Guinea	8.9	3.7	-	5.2
Paraguay	7.1	2.5	-	4.7
Peru	33.0	9.6	-	23.4
Philippines	109.6	26.5	2.3	80.9
Poland	37.8	4.6	1.0	32.2
Portugal	10.2	1.0	0.1	9.1
Qatar	2.9	0.3	0.0	2.5
Romania	19.2	2.3	-	16.9
Russia	145.9	31.2	1.7	113.1
Rwanda	13.0	5.9	0.4	6.6
Saint Kitts and Nevis	0.1	0.0	0.0	0.0
Saint Lucia	0.2	0.0	-	0.2
Saint Vincent and the Grenadines	0.1	0.0	-	0.1
Samoa	0.2	0.1	0.0	0.1
San Marino	0.0	0.0	0.0	0.0
Sao Tome and Principe	0.2	0.1	-	0.1
Saudi Arabia	34.8	7.1	1.2	26.6
Senegal	16.7	8.2	-	8.5
Serbia	8.7	1.0	-	7.7
Seychelles	0.1	0.0	-	0.1
Sierra Leone	8.0	3.8	-	4.2
Singapore	5.9	0.6	0.1	5.2
Slovakia	5.5	0.7	0.1	4.7
Slovenia	2.1	0.3	0.6	1.3
Solomon Islands	0.7	0.3	-	0.4
Somalia	15.9	8.5	-	7.4
South Africa	59.3	13.8	-	45.5
South Korea	51.3	7.8	0.3	43.1
South Sudan	11.2	5.4	-	5.8

Spain	46.8	5.2	0.4	41.2
Sri Lanka	21.4	4.0	0.3	17.0
Sudan	43.8	20.4	-	23.4
Suriname	0.6	0.2	0.0	0.4
Sweden	10.1	1.4	0.1	8.6
Switzerland	8.7	1.0	0.1	7.5
Syria	17.5	6.3	-	11.2
Tajikistan	9.5	4.0	-	5.5
Tanzania	59.7	30.0	-	29.7
Thailand	69.8	9.1	-	60.7
Timor-Leste	1.3	0.6	-	0.7
Togo	8.3	4.3	-	4.0
Tonga	0.1	0.0	-	0.1
Trinidad and Tobago	1.4	0.2	0.0	1.2
Tunisia	11.8	3.3	-	8.5
Turkey	84.3	16.1	1.4	66.9
Turkmenistan	6.0	2.2	-	3.9
Tuvalu	0.0	0.0	-	0.0
Uganda	45.7	17.4	-	28.3
Ukraine	43.7	5.6	0.4	37.8
United Arab Emirates	9.9	0.3	0.1	9.5
United Kingdom	67.9	9.7	0.7	57.5
United States	331.0	48.1	3.8	279.1
Uruguay	3.5	0.6	0.0	2.9
Uzbekistan	33.5	7.9	-	25.5
Vanuatu	0.3	0.1	-	0.2
Venezuela	28.4	9.3	-	19.1
Vietnam	97.3	18.4	-	79.0
Yemen	29.8	13.5	-	16.3
Zambia	18.4	9.4	-	9.0
Zimbabwe	14.9	5.9	-	9.0

Abbreviation: AFR, African Region; AMR, Region of Americas; EMR, Eastern Mediterranean Region; EUR, European Region; SEAR, South-East Asia Region; WPR, Western Pacific Region.

COVID-19 vaccine coverage

Metrics included in the dataset of administered doses

- (1) **Number of vaccine doses administered.** The cumulative administered number of COVID-19 vaccine doses stratified by time, vaccine technical platform, and age group, which might include initial doses, additional doses, and booster doses.
- (2) **The number of people vaccinated at least one dose.** The number of people who have received the first dose of a multiple-dose vaccine or the dose administered for a one-dose vaccine.
- (3) **The number of people fully vaccinated.** The number of people who have completed their primary immunization series according to the vaccination schedule.
- (4) **The number of people receiving additional/booster doses.** The number of cumulative people receiving additional or/and booster doses.

Figure S1. Proportion administered by vaccine technical platforms




Figure S2. Proportion administered by vaccine types.




Figure S3. Date at which achieved one dose per 100 people in total population by countries.

The white areas represent countries that have not achieved one dose per 100 people or for which data are unavailable. The data shown here are as of October 7, 2021.




Figure S4. Vaccine coverage over time stratified by income groups and role of vaccine seller/donor or recipient.

Cumulative doses per 100 people by income group in total population (A) and target population (B). Cumulative doses per 100 people by role of vaccine seller/donor or recipient in total population (C) and target population (D). Income group was defined by the World Bank. The data on role of vaccine seller/donor or recipient was derived from COVAX.




Figure S5. Vaccine coverage stratified by SDI quintile and WHO region.

SDI, socio-demographic index from the Institute for Health Metrics and Evaluation (IHME)¹⁰.





Figure S6. Corrections between vaccine coverage and country-level vaccine acceptance.

Data on country-specific vaccine acceptance among general population was summarized through a rapid review by selecting one representative study for each country, based on comprehensive evaluation about study period, sampling method and representativeness of study participants.



Demand of COVID-19 vaccine doses

Method to calculate the demand of COVID-19 vaccine doses

In primary immunization, we assumed a two-dose schedule to get the total doses required for primary immunization of target population. With an exception of previous infected COVID-19 patients, if countries recommended 1 dose for those groups, one-dose schedule was used instead. The target population for primary immunization was presented in Table S2.

In additional/booster immunization programs, we assumed a one-dose schedule for those target population recommended by each country, respectively (Table S3). Generally, the target groups for an additional dose mainly contained some specific population groups, e.g., people undergoing immunosuppression, and/or elderly, and/or specific population groups at high risk of infection (such as international travelers, front-line workers). While the target groups for a booster dose may include people with specific age, and/or people undergoing immunosuppression, and/or frontline workers, and/or people receiving Sinovac/Sinopharm vaccine.

By multiplying the number of specific target population and required doses, we obtained the doses required for primary and additional/booster immunization programs, respectively. Finally, we subtracted cumulative primary doses and additional/booster doses administered in each country to get the demand of COVID-19 vaccine doses for primary and additional/booster immunization programs, respectively (Table S7).

Table S7. Global, regional, and national demand of vaccine dose.

Locations	Doses required for vaccination (millions)			Administered doses for vaccination (millions)			Current demand doses (millions)		
	Total	Primary doses	Additional/ booster doses	Total	Primary doses	Additional/ booster doses	Total	Primary doses	Additional/ Booster doses
Global									
Total	11956.9	11031.3	925.7	6427.2	6382.4	44.7	5537.4	4650.4	887.0
WHO region									
AFR	1064.6	1062.1	2.5	86.9	86.9	-	976.1	973.6	2.5
AMR	1760.4	1582.2	178.3	1094.0	1073.5	20.5	672.1	508.7	163.4
EMR	966.0	952.2	13.8	323.8	323.5	0.3	636.4	623.0	13.5
EUR	1854.9	1501.2	353.7	993.1	972.1	21.0	870.7	538.0	332.7
SEAR	2758.4	2694.9	63.4	1244.9	1243.3	1.6	1513.4	1451.6	61.8
WPR	3552.7	3238.7	314.0	2684.3	2683.1	1.3	868.6	555.6	313.1
Countries									
Afghanistan	39.6	39.6	-	2.5	2.5	-	37.1	37.1	-
Albania	6.0	4.5	1.5	1.8	1.8	-	4.2	2.7	1.5
Algeria	57.1	57.1	-	10.6	10.6	-	46.5	46.5	-
Andorra	0.2	0.1	0.0	0.1	0.1	-	0.1	0.0	0.0
Angola	30.8	30.8	-	4.2	4.2	-	26.6	26.6	-
Antigua and Barbuda	0.2	0.2	-	0.1	0.1	-	0.1	0.1	-
Argentina	71.1	71.1	-	53.6	53.6	-	17.4	17.4	-

Armenia	4.4	4.4	-	0.5	0.5	-	3.9	3.9	-
Australia	43.2	42.4	0.8	29.6	29.6	-	13.6	12.8	0.8
Austria	24.0	15.8	8.3	10.9	10.9	-	13.1	4.8	8.3
Azerbaijan	17.2	15.9	1.3	8.9	8.9	-	8.3	7.0	1.3
Bahrain	4.2	2.8	1.3	2.6	2.3	0.3	1.5	0.5	1.0
Bangladesh	222.6	222.6	-	52.9	52.9	-	169.6	169.6	-
Barbados	0.5	0.5	0.0	0.3	0.3	-	0.3	0.2	0.0
Belarus	14.9	14.9	-	4.1	4.1	-	10.7	10.7	-
Belgium	23.3	19.8	3.5	16.9	16.7	0.2	6.4	3.1	3.3
Belize	0.6	0.6	-	0.3	0.3	-	0.3	0.3	-
Benin	12.5	12.5	-	0.2	0.2	-	12.2	12.2	-
Bhutan	1.2	1.2	-	1.1	1.1	-	0.1	0.1	-
Bolivia	15.3	15.3	-	6.9	6.9	-	8.4	8.4	-
Bosnia and Herzegovina	5.8	5.8	-	1.2	1.2	-	4.6	4.6	-
Botswana	2.9	2.9	-	0.7	0.7	-	2.2	2.2	-
Brazil	382.7	349.3	33.4	245.1	243.0	2.1	137.6	106.3	31.3
Brunei	0.7	0.7	0.0	0.5	0.5	-	0.2	0.2	0.0
Bulgaria	14.1	12.3	1.8	2.6	2.6	-	11.6	9.7	1.8
Burkina Faso	20.4	20.4	-	0.3	0.3	-	20.1	20.1	-
Burundi	3.5	3.5	-	0.0	0.0	-	3.5	3.5	-
Cambodia	39.8	29.2	10.7	24.4	23.5	0.9	15.4	5.6	9.8

Cameroon	27.2	27.2	-	0.5	0.5	-	26.7	26.7	-
Canada	66.9	65.2	1.7	56.8	56.8	-	10.0	8.3	1.7
Cabo Verde	0.7	0.7	-	0.4	0.4	-	0.3	0.3	-
Central African Republic	1.5	1.5	-	0.2	0.2	-	1.3	1.3	-
Chad	20.1	20.1	-	0.2	0.2	-	19.9	19.9	-
Chile	45.4	34.9	10.5	33.2	29.5	3.7	12.2	5.4	6.7
China	2713.2	2437.5	275.7	2217.6	2217.6	-	495.6	220.0	275.7
Colombia	94.4	82.4	12.0	42.3	42.3	0.0	52.1	40.1	12.0
Comoros	1.0	1.0	-	0.4	0.4	-	0.6	0.6	-
Congo	5.8	5.8	-	0.4	0.4	-	5.4	5.4	-
Cook Islands	0.0	0.0	-	0.0	0.0	-	0.0	0.0	-
Costa Rica	8.5	8.5	-	5.8	5.8	-	2.7	2.7	-
Cote d'Ivoire	27.3	27.3	-	2.5	2.5	-	24.8	24.8	-
Croatia	6.9	6.9	-	3.5	3.5	-	3.4	3.4	-
Cuba	22.2	22.2	-	22.3	16.7	5.7	5.6	5.6	-
Cyprus	2.5	2.1	0.4	1.2	1.2	0.0	1.3	0.9	0.4
Czechia	28.1	18.5	9.6	11.9	11.8	0.0	16.3	6.7	9.6
Democratic Republic of the Congo	31.0	31.0	-	0.1	0.1	-	30.9	30.9	-

Denmark	11.6	10.0	1.6	8.8	8.7	0.1	2.7	1.2	1.5
Djibouti	1.3	1.3	-	0.1	0.1	-	1.2	1.2	-
Dominica	0.1	0.1	-	0.0	0.0	-	0.1	0.1	-
Dominican Republic	24.9	16.5	8.5	12.1	11.1	1.0	12.9	5.4	7.5
Ecuador	27.6	27.5	0.1	21.2	21.2	-	6.4	6.3	0.1
Egypt	124.7	124.7	-	19.8	19.8	-	104.9	104.9	-
El Salvador	15.8	11.4	4.4	7.9	7.7	0.2	7.9	3.6	4.2
Equatorial Guinea	1.6	1.6	-	0.4	0.4	-	1.2	1.2	-
Eritrea	-	-	-	-	-	-	-	-	-
Estonia	3.2	2.1	1.1	1.5	1.5	-	1.7	0.6	1.1
Eswatini	1.6	1.6	-	-	-	-	-	-	-
Ethiopia	54.3	54.3	-	3.9	3.9	-	50.4	50.4	-
Fiji	1.2	1.2	-	1.1	1.1	-	0.2	0.2	-
Finland	9.9	9.5	0.4	7.8	7.8	-	2.1	1.7	0.4
France	98.1	77.8	20.3	96.0	94.5	1.5	18.9	0.0	18.9
Gabon	3.1	3.1	-	0.2	0.2	-	2.9	2.9	-
Georgia	6.0	6.0	-	1.8	1.8	-	4.1	4.1	-
Germany	159.0	142.9	16.1	108.8	107.9	1.0	50.1	35.0	15.1
Ghana	35.2	35.2	-	2.2	2.2	-	33.0	33.0	-
Greece	21.8	18.7	3.1	12.3	12.3	-	9.5	6.4	3.1

Grenada	0.2	0.2	-	0.1	0.1	-	0.1	0.1	-
Guatemala	20.7	20.7	-	7.5	7.5	-	13.2	13.2	-
Guinea	13.1	13.1	-	1.9	1.9	-	11.2	11.2	-
Guinea-Bissau	2.0	2.0	-	0.1	0.1	-	1.9	1.9	-
Guyana	1.0	1.0	-	0.6	0.6	-	0.5	0.5	-
Haiti	14.0	14.0	-	0.1	0.1	-	13.9	13.9	-
Honduras	13.3	13.3	-	5.9	5.9	-	7.4	7.4	-
Hungary	24.9	16.9	8.0	12.5	11.6	0.9	12.5	5.4	7.1
Iceland	0.7	0.6	0.1	0.6	0.5	0.1	0.1	0.1	0.0
India	1836.9	1836.9	-	927.2	927.2	-	909.7	909.7	-
Indonesia	423.4	422.7	0.8	151.5	151.5	-	272.0	271.2	0.8
Iran	119.7	119.7	-	61.5	61.5	-	58.2	58.2	-
Iraq	45.0	45.0	-	8.1	8.1	-	36.9	36.9	-
Ireland	8.8	8.1	0.7	7.5	7.5	-	1.3	0.6	0.7
Israel	19.7	13.0	6.7	15.6	11.9	3.7	4.1	1.1	3.0
Italy	133.5	107.8	25.7	85.8	85.7	0.1	47.7	22.1	25.6
Jamaica	4.4	4.4	-	0.8	0.8	-	3.6	3.6	-
Japan	226.3	226.3	-	172.1	172.1	-	54.2	54.2	-
Jordan	14.6	14.6	-	7.1	7.1	-	7.5	7.5	-
Kazakhstan	42.6	28.4	14.2	14.6	14.6	-	28.1	13.9	14.2
Kenya	58.6	58.6	-	4.0	4.0	-	54.6	54.6	-

Kiribati	0.1	0.1	-	0.0	0.0	-	0.1	0.1	-
Kuwait	10.3	7.1	3.2	-	-	-	3.2	-	3.2
Kyrgyzstan	7.8	7.8	-	1.5	1.5	-	6.3	6.3	-
Laos	9.0	9.0	-	5.2	5.2	-	3.8	3.8	-
Latvia	3.5	3.1	0.5	1.6	1.6	-	1.9	1.5	0.5
Lebanon	10.1	9.8	0.3	3.0	3.0	-	7.1	6.8	0.3
Lesotho	2.8	2.8	-	0.4	0.4	-	2.4	2.4	-
Liberia	5.3	5.3	-	0.1	0.1	-	5.3	5.3	-
Libya	9.0	9.0	-	1.7	1.7	-	7.3	7.3	-
Lithuania	5.8	4.7	1.1	3.3	3.2	0.0	2.6	1.5	1.0
Luxembourg	1.2	1.1	0.1	0.8	0.8	0.0	0.4	0.3	0.1
Macedonia	4.1	3.6	0.5	1.5	1.5	0.0	2.5	2.1	0.5
Madagascar	29.5	29.5	-	0.4	0.4	-	29.1	29.1	-
Malawi	19.1	19.1	-	1.1	1.1	-	18.0	18.0	-
Malaysia	74.1	50.9	23.2	46.1	46.1	0.0	28.0	4.8	23.2
Maldives	0.9	0.9	-	0.7	0.7	-	0.2	0.2	-
Mali	18.6	18.6	-	0.5	0.5	-	18.2	18.2	-
Malta	0.9	0.8	0.1	0.8	0.8	0.0	0.1	0.0	0.1
Marshall Islands	0.1	0.1	-	0.0	0.0	0.0	0.0	0.0	-
Mauritania	6.2	6.2	-	1.2	1.2	-	5.0	5.0	-
Mauritius	2.2	2.2	-	1.7	1.7	-	0.5	0.5	-

Mexico	144.9	144.9	-	106.1	106.1	-	38.8	38.8	-
Micronesia	0.2	0.2	0.0	0.1	0.1	-	0.1	0.1	0.0
Moldova	6.5	6.5	-	1.4	1.4	-	5.1	5.1	-
Monaco	0.1	0.1	-	-	-	-	-	-	-
Mongolia	4.8	4.8	-	4.4	4.4	-	0.5	0.5	-
Montenegro	1.2	1.1	0.2	0.5	0.5	-	0.8	0.6	0.2
Morocco	56.3	56.3	-	42.8	42.8	-	13.5	13.5	-
Mozambique	32.6	32.6	-	3.7	3.7	-	28.9	28.9	-
Myanmar	15.9	15.9	-	12.3	12.3	-	3.7	3.7	-
Namibia	2.9	2.9	-	0.5	0.5	-	2.4	2.4	-
Nauru	0.0	0.0	-	-	-	-	-	-	-
Nepal	37.7	37.7	-	14.4	14.4	-	23.3	23.3	-
Netherlands	28.7	28.0	0.7	23.9	23.9	-	4.8	4.1	0.7
New Zealand	8.2	8.0	0.2	5.6	5.6	-	2.6	2.4	0.2
Nicaragua	8.6	8.6	-	1.0	1.0	0.0	7.6	7.6	-
Niger	21.1	21.1	-	0.6	0.6	-	20.4	20.4	-
Nigeria	208.0	208.0	-	7.1	7.1	-	200.9	200.9	-
Niue	0.0	0.0	-	-	-	-	-	-	-
North Korea	-	-	-	-	-	-	-	-	-
Norway	10.4	9.4	1.0	7.9	7.9	-	2.5	1.5	1.0
Oman	8.3	8.3	-	5.2	5.2	-	3.1	3.1	-
Pakistan	303.2	303.2	-	89.7	89.7	-	213.5	213.5	-

Palau	0.0	0.0	0.0	-	-	-	0.0	-	0.0
Panama	8.2	6.8	1.4	5.2	5.2	-	2.9	1.5	1.4
Papua New Guinea	10.5	10.5	-	0.2	0.2	-	10.3	10.3	-
Paraguay	9.4	9.4	-	4.8	4.8	0.0	4.5	4.5	-
Peru	46.9	46.7	0.1	29.9	29.9	-	17.0	16.8	0.1
Philippines	161.8	161.8	-	48.9	48.9	-	112.8	112.8	-
Poland	79.8	64.4	15.4	37.8	37.8	-	42.0	26.6	15.4
Portugal	19.7	17.1	2.7	16.1	16.1	-	3.7	1.0	2.7
Qatar	5.9	5.1	0.8	4.7	4.7	-	1.1	0.3	0.8
Romania	50.7	33.8	16.9	10.6	10.6	-	40.1	23.2	16.9
Russia	340.9	226.2	114.8	93.9	93.0	0.9	247.0	133.1	113.9
Rwanda	13.2	13.2	-	3.8	3.8	-	9.3	9.3	-
Saint Kitts and Nevis	0.1	0.1	-	0.0	0.0	0.0	0.0	0.0	-
Saint Lucia	0.3	0.3	-	0.1	0.1	-	0.2	0.2	-
Saint Vincent and the Grenadines	0.2	0.2	-	0.0	0.0	-	0.1	0.1	-
Samoa	0.2	0.2	-	0.2	0.2	-	0.0	0.0	-
San Marino	0.0	0.0	-	0.0	0.0	-	0.0	0.0	-
Sao Tome and	0.2	0.2	-	0.1	0.1	-	0.1	0.1	-

Principe									
Saudi Arabia	55.2	53.2	2.0	43.1	43.1	-	12.1	10.1	2.0
Senegal	17.0	17.0	-	1.8	1.8	-	15.2	15.2	-
Serbia	22.5	15.4	7.1	6.7	6.0	0.7	15.8	9.4	6.4
Seychelles	0.2	0.2	-	0.2	0.2	-	0.0	0.0	-
Sierra Leone	8.4	8.4	-	0.3	0.3	-	8.1	8.1	-
Singapore	10.3	10.3	-	9.6	9.2	0.4	1.1	1.1	-
Slovakia	14.2	9.4	4.8	4.7	4.7	-	9.5	4.7	4.8
Slovenia	3.2	2.5	0.7	2.2	2.2	-	1.0	0.4	0.7
Solomon Islands	0.7	0.7	-	0.1	0.1	-	0.6	0.6	-
Somalia	14.9	14.9	-	0.5	0.5	-	14.3	14.3	-
South Africa	93.4	90.9	2.5	18.6	18.6	-	74.8	72.3	2.5
South Korea	89.6	86.2	3.4	67.7	67.7	0.0	22.0	18.5	3.4
South Sudan	11.7	11.7	-	0.1	0.1	-	11.5	11.5	-
Spain	86.4	77.3	9.0	70.7	70.4	0.3	15.7	6.9	8.7
Sri Lanka	36.0	34.1	1.9	26.7	26.7	-	9.3	7.4	1.9
Sudan	46.9	46.9	-	1.5	1.5	-	45.4	45.4	-
Suriname	0.8	0.8	-	0.4	0.4	-	0.4	0.4	-
Sweden	18.1	17.1	1.0	13.9	13.9	-	4.2	3.2	1.0
Switzerland	15.3	15.0	0.3	10.6	10.6	-	4.7	4.4	0.3
Syria	22.3	22.3	-	0.9	0.9	-	21.5	21.5	-

Tajikistan	11.0	11.0	-	4.5	4.5	-	6.5	6.5	-
Tanzania	59.4	59.4	-	0.9	0.9	-	58.5	58.5	-
Thailand	182.2	121.5	60.7	57.4	55.8	1.6	124.9	65.7	59.1
The Bahamas	0.7	0.7	-	0.2	0.2	-	0.4	0.4	-
The Gambia	0.7	0.7	-	0.2	0.2	-	0.5	0.5	-
Timor-Leste	1.5	1.5	-	0.8	0.8	-	0.7	0.7	-
Togo	8.0	8.0	-	1.2	1.2	-	6.8	6.8	-
Tonga	0.1	0.1	-	0.1	0.1	-	0.0	0.0	-
Trinidad and Tobago	2.3	2.3	-	1.1	1.1	-	1.2	1.2	-
Tunisia	20.9	17.0	3.9	8.3	8.3	-	12.5	8.6	3.9
Turkey	154.0	133.7	20.3	111.7	100.2	11.5	42.3	33.6	8.8
Turkmenistan	7.8	7.8	-	-	-	-	-	-	-
Tuvalu	0.0	0.0	-	-	-	-	-	-	-
Uganda	56.6	56.6	-	2.6	2.6	-	54.0	54.0	-
Ukraine	75.5	75.5	-	13.4	13.4	-	62.1	62.1	-
United Arab Emirates	21.2	19.0	2.2	20.4	20.4	-	2.2	0.0	2.2
United Kingdom	147.3	115.0	32.3	94.2	94.2	-	53.1	20.7	32.3
United States	660.0	558.2	101.8	399.6	392.8	6.8	260.5	165.4	95.0
Uruguay	10.0	5.7	4.3	6.4	5.3	1.0	3.7	0.4	3.3

Uzbekistan	51.1	51.1	-	22.0	22.0	-	29.1	29.1	-
Vanuatu	0.3	0.3	-	0.1	0.1	-	0.3	0.3	-
Venezuela	38.3	38.3	-	16.1	16.1	-	22.2	22.2	-
Vietnam	157.9	157.9	-	50.6	50.6	-	107.3	107.3	-
Yemen	32.6	32.6	-	0.4	0.4	-	32.2	32.2	-
Zambia	18.0	18.0	-	0.8	0.8	-	17.2	17.2	-
Zimbabwe	18.0	18.0	-	5.5	5.5	-	12.5	12.5	-

Abbreviation: AFR, African Region; AMR, Region of Americas; EMR, Eastern Mediterranean Region; EUR, European Region; SEAR, South-East Asia Region; WPR, Western Pacific Region.

References

1. United States CDC. Who Is Eligible for a COVID-19 Vaccine Booster Shot? 2021. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html> (accessed October 5 2021).
2. Gavi-COVAX. COVAX, the act-accelerator vaccines pillar. 2020. <https://www.gavi.org/sites/default/files/covid/COVAX-Pillar-background.pdf>.
3. Hunt BJ. Bleeding and Coagulopathies in Critical Care. *New England Journal of Medicine* 2014; **370**(9): 847-59.
4. Clark A, Jit M, Warren-Gash C, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. *The Lancet Global health* 2020; **8**(8): e1003-e17.
5. Wang W, Wu Q, Yang J, et al. Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study. *BMJ (Clinical research ed)* 2020; **371**: m4704.
6. Global Health Data Exchange. Global Burden of Diseases, Risk Factors, and Injuries Study (GBD). 2019. <http://ghdx.healthdata.org/gbd-results-tool> (accessed October 13 2021).
7. World Health Organization. Estimated antiretroviral therapy coverage among people living with HIV (%). 2012. <https://www.who.int/data/gho/indicator-metadata-registry/imr-details/4477> (accessed October 13 2021).
8. Government of Canada. Estimates of HIV incidence, prevalence and Canada's progress on meeting the 90-90-90 HIV targets. 2018. <https://www.canada.ca/en/public-health/services/publications/diseases-conditions/summary-estimates-hiv-incidence-prevalence-canadas-progress-90-90-90.html> (accessed October 13 2021).
9. Adedinsewo DA, Wei SC, Robertson M, et al. Timing of antiretroviral therapy initiation in a nationally representative sample of HIV-infected adults receiving medical care in the United States. *AIDS patient care and STDs* 2014; **28**(12): 613-21.
10. Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2019 (GBD 2019) Socio-Demographic Index (SDI) 1950–2019. <http://ghdx.healthdata.org/record/ihme-data/gbd-2019-socio-demographic-index-sdi-1950-2019>.